001-MCS -40-106- RD-03(12.0)/Saved on:30Jan2015
CLINICAL TRIAL PROTOCOL
TITLE PAGE
Document Number: c03632269-[ADDRESS_423994] No.:    2015-005438-24
BI Trial No.: 1346.[ADDRESS_423995](s):BI 425809
Title:A multi -centre, double -blind, parallel -group, randomised 
controlled study  to investigate efficacy  and safety of orall y 
administered BI 425809 during a 12-week treatment period 
compared to placebo in patients with cognitive impairment due 
to Alzheimer ’sDisease.
Brief Title:BI 425809 in patients with cognitive impairment due to 
Alzheimer’s Disease
Clinical Phase: II
Trial Clinical 
Monitor:
Phone: , Fax: 
Coordinating 
Investigator:
[CONTACT_7626]:           Fax: 
Status: Final Protocol (Revised Protocol (based on global amendment No. 4))
Version and Date: Version: 5.0 Date: 12Jul2018
Page 1 of 77
Proprietary confidential information .
2018 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not -in full or in part -bepassed on, reproduced, published or otherwise used without prior written permission.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 2of 77
Proprietary confidential information © [ADDRESS_423996]-03(12.0)/Saved on:30Jan2015CLINICAL TRIAL PROTO COL SYNOPSIS
Nam e of company: Boehringer Ingelheim 
Nam e of finished product: NA
Nam e of active ingredient: BI 425809
Protocol date:
14Apr2016Trial number:
1346.23Revision date:
12Jul2018
Title of trial: A multi -centre, double -blind, parallel -group, randomised controlled study to 
investigate efficacy and safety of orally administered BI 425809 during a 12 -week 
treatment period compared to placebo in patients with cognitive impairment due to 
Alzheimer’s Disease.
Coordinating
Investigator:
[CONTACT_7626]:                                  
Trial site(s): Multi -centre , multi -national trial
Clinical phase: II
Objective(s): To assess safety, tolerability and efficacy of different doses of BI 425809 
compared to placebo in treatment of cognitive impairment due to A lzheimer’s 
Disease
Methodology: Placebo -controlled, double -blind, double- dummy, randomized, parallel -group 
design comparison of 5 treatment groups over 12 w eeks of treatment
No. of patients: ~950 enrolled
total entered: ~585
each treatm ent: ~117
Diagnosis : Patients with diagnosis of mild -to moderate Alzheimer’s Disease Dementia 
according to the recommendations from the National Institute on Aging -
Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s 
disease 
Main criteria
for inclusion:The population will include male and female patients at least 55 years old w ith 
mild-to-moderate Alzheimer’s Disease D ementia. A MMSE (Mini -Mental -
State-Examination) score between 15 -26is required for inclusion. A caregiver 

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 3of 77
Proprietary confidential information © [ADDRESS_423997]-03(12.0)/Saved on:30Jan2015Nam e of company: Boehringer Ingelheim 
Nam e of finished product: NA
Nam e of active ingredient: BI 425809
Protocol date:
14Apr2016Trial number:
1346.23Revision date:
12Jul2018
has to be available for study site activities and on call by [CONTACT_342338](s): BI 425809
dose: 2mg QD, 5mg QD, 10mg QD, 25mg QD 
mode of 
admin istration :Tablet, oral
Comparator 
products:Placebo matching BI 425809 1mg and 5mg
And Placebo matching BI 425809 25 m g
dose: Not applicable
mode of 
admin istration :Tablet, oral
Duration of treatm ent: 12 w eeks
Endpoints : Primary endpoint:
1.Change from baseline in ADAS -cog 11(Alzheimer’s Disease Assessment 
Scale -cognitive subscale) total score after 12 -week treatment 
Secondary endpoints include: 
2.Change from baseline in ADCS -ADL (Alzheimer’s Disease Cooperative 
Study/Activities of Daily Living) total score after 12 -week treatment 
3.CIBIC Plus total score after 12-weeks treatment 
Safety criteria : Adverse event reporting, vital signs, ECG (digital) and standard laboratory tests, 
Columbia -Suicide Severity Rating Scale (C -SSRS).
Statistical m ethods: The primary objective is to define a suitable dose for BI 425809 regarding efficacy 
and safety for further pi[INVESTIGATOR_342324]. For this purpose, a multiple 
comparison procedure w ith modelling (MCPmod) approach is considered. The 
primary endpoint is mean change from baseline in ADAS -Cog11 total score after 12 
weeks of treatment. Comparisons between treatment groups will be exploratory in 
nature and based on the numerical comparison of the respective treatment 
differences including confidence intervals when appropriate .
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 4of 77
Proprietary confidential information © [ADDRESS_423998]-03(12.0)/Saved on:30Jan2015FLOW CHART
Trial Period Screening Treatment Period Follow -up
Visit0121 2
Baseline 3a93b93c94 5EOT/
ED8FU111FU2
Study -Day (or duration during 
screening/ run -in)Duration 
14days1 8 15 22 29 57 85EOT
+7EOT
+28
Study Week -2 1 2 3 4 8 12 13 16
Visit window (in days)+7 to      
-2820±2 ±2 ±2 ±5 ±5+5 +2 +5
Patient information & informed 
consent signed (including informed 
consent for PGx)1X
Register Patient in I RT X17
Randomisation (via I RT) X18
Register Patient’s End of Study Call  
in IRTX
Demographics (of patient and study 
partner)X
Medical history / baseline conditions X
In-/exclusion criteria X X X
Imaging of the Brain2X
Concomitant medications13X X X X X X X X X X X
Height (screening only)/weight X X X
Vital signs X X X X9X9X X X X
Physical examination X X
Neurological examination X X
Resting ECG (digital) X X16X9, 16X9, 16X16X16X16
Adverse events X X X X X9X9X X X X X
Dispense trial medication3X X X
Last dose of trial medication X
Collect study drug X X X
Medication Compliance Check X X X
Laboratory tests: Chemistry, 
haematology, urin e analysisX14X X X X X
Urine drug screen X X
Neuropsychological Rating Scales19
MMSE X
ADAS -cog 11 X X10X10X10
CIBI S X10
CIBI C+ X10
ADCS -ADL X X10X10
Prospective Suicidality 
Monitoring19
C-SSRS X6X7X7X7X7X7X7X7X7X7

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 5of 77
Proprietary confidential information © [ADDRESS_423999]-03(12.0)/Saved on:30Jan2015Trial Period Screening Treatment Period Follow -up
Visit0121 2
Baseline 3a93b93c94 5EOT/
ED8FU111FU2
Study -Day (or duration during 
screening/ run -in)Duration 
14days1 8 15 22 29 57 85EOT
+7EOT
+28
Study Week -2 1 2 3 4 8 12 13 16
Visit window (in days)+7 to      
-2820±2 ±2 ±2 ±5 ±5+5 +2 +5
Comple tion of patient 
participationX
Vital status collection15X
1Prior to any trial related procedures, including any pre-trial washout of medications and /or medication restrictions (for more 
details on medication restrictions refer to Section [IP_ADDRESS] ). 
[ADDRESS_424000] to be available prior to visit 2. Please refer to Exclusion #1 in Section 3.3.3 for further details. 
3 At all visits, the respective kit number has to be allocated to the patient via IRT
6  Columbia Suicide Severity Rating Scale baseline/screening version
[ADDRESS_424001] discontinued the trial prematurely not willing to come to 
remaining trial visits : in case of early termination visit FU1 should preferably be performed no later than [ADDRESS_424002] 
study drug intake (visit FU 2should follow four weeks later). 
9If the assessments at visit 3 a do not show clinically relevant findings compared to baseline and if deemed clinically acce ptable b y 
the investigator then visits 3b and 3 c may be performed as phone contacts. Attendance of the study partner is not nece ssarily 
required during visits 3 a-c. ECG and vital signs are only to be performed at clinic visits. At any of visit 3 (i.e. vis it 3a to 3b ) 
the IMP may be taken at home.
10The neuropsychological assessments may be performed one day before the actual clinic visit if agreed between site staff and 
patient. In any case it needs to be ensured that the recommendations for the conduct of the neuropsychological assessments 
(refer to Section 6.2 for details) are followed. Neuropsychological rating scales a ssessments need to be done inone day and 
may not be split in two individual days.
11 This visit can be done as phone or clinic visit
12 Visit0can be performed on the same day with Visit 1 (the Screening Visit) if there is no need to make these visits separate (e.g.
medication washouts, CCT or MRI scan availability )
13 Refer to section [IP_ADDRESS] to check for concomitant medication restrictions, requirements including any pre -trial washout of 
medications
14 Laboratory parameters: Haemoglobin, GFR, ALT, AST and alkaline phosphatase found abnormal at visit 1 may be re -tested twice
prior to Visit 2. If Vitamin B12 and/or folate are found below lower limit normal, please initiate the respective treatment to 
stabilise the condition. Vitamin B12 and/ or folate re -test may be done twice prior to Visit 2. For possible extensions of 
screening period refer to Section 6.[ADDRESS_424003] procedure at the clinic visit in the order pre-set in the rater station (the order 
of the scales in the rater station is consistent with the protocol Flow Chart ).
20The screening period may be shorten to a minimum of 7 days if all screening procedures and results are available. At the 
same time the screening period may be extended by [CONTACT_168984] 4 weeks (28 days) for any reasons. For further details please 
refer to Section 6.1 .

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 6of 77
Proprietary confidential information © [ADDRESS_424004]-03(12.0)/Saved on:30Jan2015TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................... 1
CLINICAL TRIAL PROTO COL SYNOPSIS ................................
..................................... 2
FLOW CHART ........................................................................................................................ 4
TABLE OF CONTENTS ........................................................................................................ 6
ABBREVIATIONS .................................................................................................................. 9
1. INTRODUCTION ............................................................................................... 12
MEDICAL BACKGROUND ............................................................................. 12 1.1
DRUG PROFILE ................................................................................................ 13 1.2
2.
RATIONALE, OBJECTIVES, AND BE NEFIT -RISK ASSESSMENT .....15
RATIONALE FOR PERFOR MING THE TRIAL ......................................... 15 2.1
TRIAL OBJECTIVES ........................................................................................ 15 2.2
BENEFIT - RISK ASSESSMENT ..................................................................... 15 2.3
3. DESCRIPTION OF DESIG N AND TRIAL POPULATI ON......................... 17
OVERALL TRIAL DESIGN AND PLAN ....................................................... 17 3.1
3.1.1 Administrative structure of the trial ................................
................................. 17
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOIC E OF 3.2
CONTROL GROUP(S) ...................................................................................... 18
SELECTION OF TRIAL P OPULATION ....................................................... 19 3.3
3.3.1 Main diagnosis for trial entry ............................................................................ 19
3.3.2 Inclusion criteria
................................................................................................. 19
3.3.3 Exclusion criteria ................................................................................................ 20
3.3.4 Removal of patients from therapy or assessments........................................... 22
[IP_ADDRESS] Removal of individual patients .......................................................................... 22
[IP_ADDRESS] Discontinuation of the trial by [CONTACT_456] ....................................................... [ADDRESS_424005](s) and comparator product(s) ........... 24
4.1.2 Method of 
assigning patients to treatment groups ........................................... 26
4.1.3 Selection of doses in the trial .............................................................................. 26
4.1.4 Drug assignment and administration of doses for each patient ...................... 27
4.1.5 Blinding and procedures for unblinding ........................................................... 27
[IP_ADDRESS] Blinding ................................
................................................................................ 27
[IP_ADDRESS] Unblinding and breaking the code .................................................................... 28
4.1.6 Packaging, labelling, and re- supply ................................................................... 28
4.1.7 Storage conditions ............................................................................................... 28
4.1.8 Drug accountability ................................
............................................................. 28
CONCOMITANT THERAPY, RESTRICTIONS, AND RE SCUE  4.2
TREATMENT ..................................................................................................... 29
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 7of 77
Proprietary confidential information © [ADDRESS_424006]-03(12.0)/Saved on:30Jan20154.2.1 Rescue medication, emergency procedures, and additional treatment(s) ..... 29
4.2.2 Restrictions ................................................................
.......................................... 29
[IP_ADDRESS] Restrictions regarding concomitant treatment ................................................ 29
[IP_ADDRESS] Restrictions on diet and life style ....................................................................... 34
TREATMENT COMPLIANCE ........................................................................ 34 4.3
5. VARIABLES AND THEIR ASSESSMENT .................................................... 35
TRIAL ENDPOINTS .......................................................................................... 35 5.1
5.1.1 Primary Endpoint(s) ........................................................................................... 35
5.1.2 Secondary Endpoint(s) ....................................................................................... 35
ASSESSMENT OF EFFICA CY........................................................................ 35 5.2
ASSESSMENT OF SAFETY ................................
............................................. 37 5.3
5.3.1 Physical examination .......................................................................................... 37
5.3.2 Vital Signs ............................................................................................................ 37
5.3.3 Safety laboratory parameters ................................
............................................ 37
5.3.4 Electrocardiogram .............................................................................................. 39
5.3.5 Other safety parameters..................................................................................... 40
[IP_ADDRESS] Suicidal risk assessed by [CONTACT_941] C -SSRS ................................................................ 40
5.3.6 Assessment of adverse events ............................................................................. 41
[IP_ADDRESS] Definitions of AEs ................................................................................................ 41
5.3.7 Adverse event collection and reporting ............................................................. 44
6. INVESTIGATIONAL PLAN ............................................................................. 48
VISIT SCHEDULE ............................................................................................. 48 6.1
DETAILS OF TRIAL PR OCEDURES AT SELECTED VISITS ................. 48 6.2
6.2.1 Screening and run -in period(s) .......................................................................... 49
6.2.2 Treatment period(s) ................................
............................................................ 49
6.2.3 Follow Up Period and Trial Completion ........................................................... 50
7. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
................................................................
............................................................... 52
STATISTICAL DESIGN – MODEL ................................................................ 52 7.1
NULL AND ALTERNATIVE HYPOTHESES ............................................... 52 7.2
PLANNED ANALYSES ..................................................................................... 52 7.3
7.3.1 Primary endpoint analyses ................................................................................. 53

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 8of 77
Proprietary confidential information © [ADDRESS_424007]-03(12.0)/Saved on:30Jan20157.3.1.1 Primary analysis of the primary endpoint ................................ ........................ 53
[IP_ADDRESS] Secondary analyses of the primary en dpoint .................................................. [ADDRESS_424008] access to source data and documents..................................................... 62
8.3.3
Storage period of records ................................................................................... 62
LISTEDNESS AND EXPEDITED REPORTING OF AD VERSE EVENTS 62 8.4
8.4.1 Listedness ............................................................................................................. 62
8.4.2 Expedited reporting of adverse events .............................................................. 62
STATEMENT OF CONFIDE NTIALITY ........................................................ 63 8.5
TRIAL MILESTONES ....................................................................................... 63 8.6
PROTOCOL VIOLATIONS ................................
............................................. 63 8.7
COMPENSATION AVAILAB LE TO THE PATIENT IN THE EVENT OF 8.8
TRIAL RELATED INJURY .............................................................................. 64
9. REFERENCES .................................................................................................... 65
PUBLISHED REFERENCES ................................
............................................ 65 9.1
UNPUBLISHED REFERENC ES...................................................................... 67 9.2
11. DESCRIPTION OF GLOBA L AMENDMENT(S) ......................................... 70

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 9of 77
Proprietary confidential information © [ADDRESS_424009]-03(12.0)/Saved on:30Jan2015ABBREVIATIONS
ABCB1 ATP -binding cassette sub- family  B member 1 (gene encoding for P -gp)
AChE -Is Acet ylcholine Esterase Inhibitor s
AD Alzheimer’s Disease
ADAS -cog Alzhei mer's Disease Assessment Scale -Cognitive subscale
ADCS -ADL Alzheimer’s Disease Cooperative Study /Activities of Daily  Living
AE Adverse Event
AESI Protocol -specified Adverse Event of Special Interest
AIC Akaike Information Criterion
AUC Area under the Curve
CCT Cranial Computer Tomograph y
CI
CIBIC+
CIBISConfidence Interval
Clinician's Interview -Based I mpression of Change
Clinical I nterv iew-Based I mpression of Severity
CML Local Clinical Monitor 
CRA Clinical Research Associate
CRF Case Report Form
CSF Cerebrospi[INVESTIGATOR_17106]
C-SSRS Columbia Suicide Severity  Rating Scale
CT Computer Tomograph y
CTCAE Common Terminology  Criteria for Adverse Events
CTMF Clinical Trial Master File
CTP Clinical Trial Protocol
CTR Clinical Trial Report
CYP Cytochrome P450
DEDP Drug Exposure D uring P regnancy
DMC Data Monitoring Committee
eCRF Electronic Case Report Form
ED Early discontinuation
EDC Electronic Data Capture
ERG Electroretinogram
EudraCT European Clinical Trials Database
FAS Full Anal ysis Set
GCP Good Clinical Practice
GlyT1 Glycin Transporter 1
HEENT Head -Eyes-Ears- Nose -Throat
HPC Human Pharmacology  Centre
i.v. Intravenous
IB Investigator’s Brochure
IEC Independent Ethics Committee
IM Intermediate metabolizer

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 10of 77
Proprietary confidential information © [ADDRESS_424010]-03(12.0)/Saved on:30Jan2015IRB Institutional Review Board
IRT Interactive Response Technology
ISF Investigator Site File
LC-MS Liquid Chromatograph y tandem Mass Spectrometry
LTP Long Term Potentation
MCPmod Multiple Comparison P rocedures and modelling
MedDRA Medical Dictionary  for Drug Regulatory  Activities
MMRM Mixed Model Repeated M easures
MMSE Mini -Mental -State -Examination
MRI Magnetic Resonance Imaging
MST Medical Subteam
NMDA-R N- methy l-D-aspartate receptor
NOA Not anal yzed
NOP No peak detectable
NOR No valid result
NOS No sample available
OPU Operative Unit
p.o. per os (oral)
PDE9 Phosphodiesterase -9
PG(x) Pharmacogenomic(s)
P-gp P-glycoprotein
PK Pharmacokinetic
PM Poor metabolizers
POC Proof of Concept
PSA Prostate Specific Antigen
PTM Placebo to Match
q.d. quaque die (once a day )
RDC Remote Data Capture
REP Residual Effect Period
RNA Ribonucleic Acid
RPR Rapid Plasma Reagin
s.c. Subcutaneous
SAE Serious Adverse Event
SP(1) Spatial 
SPC Summary  of Product Characteristics
STORM Storage Conditions for Trial Medications
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
TCM Trial Clinical Monitor
TDMAP Trial Data Management and Anal ysis Plan
tmax,ss Time to maximum plasma concentration (at steady  state)
TMM Team Member Medicine
TMW Trial Medical Writer
TSAP Trial Statistical Analy sis Plan
UM Ultrarapid metabolizer

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 11of 77
Proprietary confidential information © [ADDRESS_424011]-03(12.0)/Saved on:30Jan2015UN Unstructured

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 12of 77
Proprietary confidential information © [ADDRESS_424012]-03(12.0)/Saved on:30Jan20151. INTRODUCTION
MEDICAL BACKGROUND 1.1
Alzheimer’s Disease Dementia , a chronic progressive mental disorder caused by  [CONTACT_7351]’s 
Disease (AD), is the most common cause of dementia and accounts for 50 to 70% of all 
cases. AD is mainl y a disorder of the elderl y; however it can also affect patients below the 
age of 60. More than [ADDRESS_424013] 
of them suffering from AD, with around 5 million new cases occurring every  year [R10-
5095 ; R10-5106]. The age -specific prevalence of AD almost doubles every 5 y ears after age 
65. Among developed nations, approximately  1 in 10 elderl y people (65+ years) is affected 
by [CONTACT_342339], whereas more than one third of the very  old people (85+ y ears) 
may have demen tia-related sy mptoms and signs [ R10-5105].
In the early  stage of the clinical disease manifestation cardinal s ymptoms are characterized by  
[CONTACT_342340][INVESTIGATOR_342325], like executive function, 
orientation and judgment. This is followed by  a progressive decline in the ability  to perform 
activities of daily  living and the appearance of behavioural changes and/or psy chiatric 
symptoms (mood disturbances, hallucinations, personality
 changes). With progression of the 
disease there is an increasing utilization of resources and medical care finally  leading to the 
need of full -time assisted living or nursing home care before death. The median time from 
onset of sy mptoms to death is estimated to be around 10 y ears.
The pattern of cognitive and functional decline is not uniform over the course of the disease 
and differs according to the measure in question and the scales used. Cognitive decline, for 
example, seems to be more rapid in the moderate and severe stages than in the mild and very  
severe stages, yielding a sigmoid curve of progression.
Currently  approved AD treatment is used to treat the impairments in memory  and function in 
patients with dementia
.Registered s ymptomatic treatment is possible with 
acetylcholinesterase inhibitors (AChE -Is) and memantine. Donepezil, galan tamine, and 
rivastigmine are the three widely  registered AChE -Is for the treatment of mild to moderate 
AD. Donepezil is also approved for severe AD in the US and Canada. Memantine, an 
uncompetitive N- methy l-D-aspartate (NMDA ) receptor antagonist, is registered in Europe 
and in the US for the treatment of moderate to severe AD. 
Currently , AChE -Is in general and donepezil in particular can be regarded as gold standard 
for treatment of mild -to-moderate AD.
On cellular level AD is characterized by  a progressive loss of sy napses and neurons. Affected 
transmitter sy stems mainly  include cholinergic and glutamatergic neurons. Glutamate as the 
major excitatory  neurotransmitter in the human brain is most prominently  associated with 
functions of memory  formation and learning. Glutamatergic transmission is mediated by  
[CONTACT_342341] -synaptic NMDA receptor play ing an essential role. GlyT1 
inhibition increases pos t-synaptic NMDA receptor signal ing and BI [ADDRESS_424014] -
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 13of 77
Proprietary confidential information © [ADDRESS_424015]-03(12.0)/Saved on:30Jan2015synaptic signalling events is triggered through elevation of second messengers such as cAMP 
and cGMP with subsequent activation of protein kinases and manifestation of long-term 
potentiation (L TP) and sy naptic plasticity . LTP is regarded as a validated phy siological 
model for cellular processes underl ying learning and memory  formation [ R10-5109; R10-
5092 ; R10-5102].
DRUG PROFILE 1.[ADDRESS_424016] to classic 
antipsy chotic therap y.
Schizophrenia and AD are chronic, severe, and disabling brain disorders affecting both men 
and women. 
Both disorders are characterized by  [CONTACT_342342] h ypofunction in cortical and hippocampal brain areas [ R13-4518; R13-
4521 ]. These abnormalities are h ypothesized to lead to negative s ymptoms and cognitive 
impairment in schizophrenia and cognitive impairment in AD. 
Inhibition of GLYT1 aims at improvin g NMDA receptor h ypo-activation in patients with 
schizophrenia and AD b y increasing the concentration of the NMDA receptor co -activator 
glycine in the s ynaptic cleft, thereb y leading to improvement of negative and cognitive 
symptoms in patients with schizo phrenia (as add -on therap y to antips ychotics) as well as to 
cognitive improvement in AD patients.
Based on in vitro data, at the highest proposed Phase 2 dose of 25 mg, BI 425809 may 
cause clinically relevant induction of CYP2B6 . Based on a Phase I clinica l study BI 
425809 is a mild CYP3A4 inducer at 25mg. Based on clinical DDI stud y BI with 
itra
conazole and rifampi[INVESTIGATOR_342326] 425809 is a sensitive CYP3A4 substrate and should not be 
given with moderate -to-strong inhibitors or inducers of CYP3A4.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 14of 77
Proprietary confidential information © [ADDRESS_424017]-03(12.0)/Saved on:30Jan2015Clinical Safety  Pharmacology
In health y volunteers, BI [ADDRESS_424018] commonly  headaches that showed a trend for dose 
dependency , were reversible and can be clinicall y monitored. I n addition, BI 425809 may  be 
associated with transient visual disturbances, and somnolence (drowsiness). These effects are 
understood to be mostly  mild to moderate and transient. Decreased haemoglobin is a potential 
risk based on preclinical dat a and class effect; however, no clear decrease in haemoglobin 
was seen in BI 425809- treated subjects compared to placebo in phase I trials so far.
No serious safety  concerns have been identified with administration of GLYT1 inhibitors in 
humans. The most frequent adverse events were CNS effects and visual effects. Visual 
effects are generally seen at higher doses and are transient in nature. Visual AEs and changes 
in Hb levels should be anticipated with GLYT1 inhibitors and are of special interest and 
should be closely  monitored. Additionally , CNS effects should be anticipated and are 
expected to be dose -limiting.
For a more detailed description of t he drug profile refer to the current Investigator’s Brochure
(IB) which is included in the Investigator Site File ( ISF).

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 15of 77
Proprietary confidential information © [ADDRESS_424019]-03(12.0)/Saved on:30Jan20152. RATIONALE , OBJECTIVES, AND BE NEFIT -RISK 
ASSESSMENT
RATIONALE FOR PERFOR MING THE TRIAL 2.[ADDRESS_424020] for 
treatment of mild -to-moderat e AD.  However, there is still a high unmet medical need for 
additional sy mptomatic therapi[INVESTIGATOR_342327]-to-moderate dementia of Alzheimer’s t ype.
This study  is performed to define a suitable dose ofBI 42 5809 regarding efficacy  and safety  
for furth er pi[INVESTIGATOR_342328] I.The main rationale for this study  is to provide proof of 
clinical concept and dose ranging data in patients with mild -to-moderate dementia of 
Alzheimer’s ty pe aged at least 55 yearsat enrolment .
TRIAL OBJECTIVES 2.2
The proof of clinical concept will be achieved through primary  endpoint comparison (mean 
change from baseline in ADAS- Cog 11total score at Week 12) of the four BI doses (2mg QD, 
5mg QD, 10mg QD and 25mg QD) and placebo.  A non- flat dose response relationship 
between the BI doses and placebo will be tested using the multiple comparison procedures 
and modelling (MCPmod ) approach [R10-1424, 
R15-1961].
Other objectives of this study  are safety  of BI 
425809.
BENEFIT - RISK ASSESSMENT 2.[ADDRESS_424021] further studies with this molecule. Currentl y available data
comprising of six phase 1 trialsresults involved in total 229 healthy  subjects treated with 
single or multiple doses of orall y administered BI 425809 up to 150 mg per day . 
Based on non -
clinical data, clinical data from other compounds in the same class, and 
subjects exposed in phase I trials; BI 425809 is assessed to be generall y safe and well 
tolerated [c02155957-07].

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 16of 77
Proprietary confidential information © [ADDRESS_424022]-03(12.0)/Saved on:30Jan2015Although rare, a potential for drug -induced liver injury  is under constant surveillance by  
[CONTACT_23274]. Therefore, this trial requires timely  detection, evaluation, and 
follow -up of laboratory  alterations in selected liver labor atory  parameters to ensure patients´ 
safet y, see also Section [IP_ADDRESS] .
This is newly  developed drug at an earl y stage of testing and therefore an individual benefit 
cannot be guaranteed. 
This is a trial of short duration and the assignment to the placebo arm is not associated with a 
higher risk for the patient .1 out of 5 patients will be randomised to the placebo arm. The 
study  procedures (e.g. AD assessment, safety  and suicidality  monitoring etc.) may  in fact 
benefit the pat ients e.g. intensive medical care, a potentially  better knowledge of the 
underly ing disease which may  lead to a better handling of this disease. Also, this disease is 
not reversible and can last more than [ADDRESS_424023] benefit for th e patient 
during participation in this trial, it can be assumed that the trial results may  contribute to 
better drug development in future. In addition, due to the long duration of the disease the 
patient may  directl y benefit from the drug development base d on the results of this trial. 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 17of 77
Proprietary confidential information © [ADDRESS_424024]-03(12.0)/Saved on:30Jan20153. DESCRIPTION OF DESIG N AND TRIAL POPULATI ON
OVERALL TRIAL DESIGN AND PLAN 3.1
This is a 12- week, multi -centre, multi- national, r andomised, double -blind, double -dummy , 
placebo controlled, parallel group comparison in patients with mild -to-moderate Alzheimer’s 
Disease Dementia . In total, 
585patients with mild -to-moderate Alzheimer’s Disease 
Dementia who meet the entry  criteria are planned to be randomised in this trial. The 
randomised treatment will be double blind. 
All patients suitable after screening will be randomised in to 12-week double -blind treatment 
period at Visit 2 and will be assigned to one of the 4treatment groups or placebo , refer to 
Figure 3.1: 1.
Figure 3.1: 1 Trial Design
After the end of the double -
blind treatment period, patients will be followed up for additional 
4 weeks without study  medication. Safety will be formally evaluated at each visit until end of 
the observational period which is 28 days after end of treatment or for an appropriatel y longer 
time in case of unresolved adverse events.
3.1.1 Administrative structure of the trial
Boehringer Ingelheim has appointed a Trial Clinical Monitor, responsible for coordinating all
required activities, in order to 
manage the trial in accordance with applicable regulations and internal SOPs,
direct the clinical trial team in the preparation, conduct, and reporting of the trial,
ensure appropriate training and information of local cl inical monitors (CML), Clinical 
Research Associates ( CRA s), and Investigator s of participating countries.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 18of 77
Proprietary confidential information © [ADDRESS_424025]-03(12.0)/Saved on:30Jan2015Bracket Global has been selected as service provider to support tasks related to the 
neurops ychological assessments: necessary rater prequalification , rater training (online and at 
investigator meeting), provision of rater materials and cent ral review of neuropsy chological 
assessments (see 
Section 8. 3.1for details).
Data Management and Statistical Evaluation will be d one b y BI according to BI SOPs.
Tasks and functions assigned in order to organi se, manage, and evaluate the trial will b e 
defined according to BI SOPs. A list of responsible persons and relevant local information
can be found in the I SF.
Central laboratory  and central ECG service vendors will be used for this trial. The 
organization of the trial in the participating countries will be done by
 [CONTACT_342343] (OPU) or by  a Contract Research organization (CRO) with which the 
responsibilities and tasks have been agreed and a written contract has been filed before 
initiation of the clinical trial. I n each local BI -organisation (OPU) participating in this study , 
a local clinical monitor (CML ) will be appointed responsible for coordinating the activities 
required in order to manage the trial in accordance with applicable regulations and internal 
SOPs in the countries covered b y the respective BI OPU.
A Coordinating Investigator [INVESTIGATOR_342329] s at different centres participating in this multicentre trial. The Co ordina ting 
investigator was selected by  [CONTACT_456].  will review the trial protocol, any subsequent 
amendments to the protocol and the (draft) Clinical Trial Report (CTR) .Relevant 
documentation on the participating (Principal) Investigators and other importa nt trial staff 
shall be filed in the I SF.
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOICE OF 3.2
CONTROL GROUP(S)
A parallel group design is the appropriate design as the inherent within -patient variability  and 
the progressive nature of the disease makes it difficult if not impossible to employ  a 
crossover design.
In order to estimate the relative drug effect on cognition and function, a double -blind 
comparison against placebo is included in this trial. 
The current standard treatment of cognitive and functional impairment in AD shows 
substantial treatment effects during the first three months of treatment. Therefore, a [ADDRESS_424026] 
in this indication and will provide important information in terms of effica cy and safet y on 
the use of BI 425809 in patients with mild -to-moderate AD.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 19of 77
Proprietary confidential information © [ADDRESS_424027]-03(12.0)/Saved on:30Jan2015SELECTION OF TRIAL P OPULATION 3.[ADDRESS_424028] is kept 
of all patients failing to complete all trial visits and their reasons for discontinuation. 
This tr ial aims to randomise approximately  half of patients with mild Mini -Mental State 
Examination ((
MMSE )20-26) andhalf with moderate (MMSE 15- 19) AD .The 
sponsor/study  team will monitor recruitment closely  and reserves the right to stop further 
enrollment of either mild or moderate patients in order to meet this goal. 
Permission to randomise more than [ADDRESS_424029] be obtained from the TCM at 
Boehringer Ingelheim. This shall only be allowed after a careful review of the data qualit y 
and the performance of the site .
A log of all patients enrolled into the trial(i.e. who have signed informed consent) will be 
maintained in the I SF at the investigational site irrespective of whether they  have been treated 
with investigational drug or not.
3.3.1 Main diagnosis for trial entry
Patients with the diagnosis of mild -to-moderate Alzheimer’s Disease Dementia (according to 
the Core Clinical Criteria of the recommendations from the National Institute on Aging -
Alzheimer’s Association workgroups [ R13-4115] on diagnostic guidelines for Alzheimer’s 
Disease Dementia) will be included.
Please refer to Section 8.3.1 (Source Documents) for the documentation requirements 
pertaining to the in -and exclusion criteria.
3.3.2 Inclusion criteria
1.Diagnosis of mild -to-moderate Alzheimer’s Disease Dementia according to the 
recommendations from the Natio nal Institute on Aging -Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s disease (see Section 3.3.1 ).
2.MMSE score of 15- 26 at screening (Visit 1) .
3.Concomitant use of AChEI s is allowed but not required. Patients who are currentl y 
taking AChEIs are eligible as long as they  have been using a stable dose for at least [ADDRESS_424030] sign and date an Informed Consent Form consistent with ICH- GCP
guidelines and local legislation prior t o participation in the trial (i.e. prior to any trial 
related procedures, including any pre- trial washout of medications/medication 
restrictions, Section 4 .2.2.1.) 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 20of 77
Proprietary confidential information © [ADDRESS_424031]-03(12.0)/Saved on:30Jan2015All patients must be able to give informed consent personally and have capacity for 
such consent. An informed consent given by a legal representative alone will not be 
accepted . 
5.Patients must have a reliable study  partner (per investigator jud gment ,for instance a 
family  member, partner etc., guardian (must be alway s the same person)) who is in close 
contact [CONTACT_10970], available on call and who is able to contribute to the 
Neurops ychological Rating Scales at specific study  visits as stat ed in the Flow Chart. 
This person will be able to communicate in the language in which the patient is being 
assessed and should also serve as a backup contact [CONTACT_342344] y site. The study partner 
must sign a separate informed consent form which describes their contributions during 
the study .
6.Patients must have at least [ADDRESS_424032] 55 y ears of age. Patients older than 85 y ears may  be 
included based on an acceptable general health status, (e.g. concomitant diseases, 
physical capabilit y to follow the required study  procedures ( visits etc. )) at discretion of 
the invest igator. 
3.3.3 Exclusion criteria
1.Dementia secondary  to disorders other than Alzheimer's Disease Dementia
(for example: Vitamin B12/Folate deficiency , neurosy philis, craniocerebral trauma, 
small vessel disease ). Lewy body  dementia or vascular or multi -infarct dementia as
primary  diagnosis is excluded. The above should be assessed 
based on clinical data , 
current laboratory  findings , and a MRI or CT of the brain.
If previous cranial imaging is not available or older than [ADDRESS_424033] is not allowed (e.g. [LOCATION_013], [LOCATION_009]), a MRI must be 
performed.
2.Any central nervous s ystem disease other than ADwhich 
according to the investigator 
may be associated with worsening of cognition. Patients with epi[INVESTIGATOR_342330] 2 
years should be excluded.
3.A disease or condition which in the opi[INVESTIGATOR_342331]. 
4.Any documented active or suspected malignancy  or history  of malignancy  with need of 
concomitant treatment that interfere with 
the investigational produc t. 
5.Patients with life expectancy of less than 2 years are also excluded.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 21of 77
Proprietary confidential information © [ADDRESS_424034]-03(12.0)/Saved on:30Jan20156.Any other clinical condition that, in the opi[INVESTIGATOR_871], would jeopardize 
patient safet y while participating in this clinical trial.
7.Severe renal impairment defined as a GFR < 30 mL/min/1.73 m2 in the screening 
central lab report.
8. Haemoglobin less than 120 g/L (12 g/dL) in men or 1 15g/L (11.5 g/dL) in women in the 
screening lab report .History  of haemoglobinopathy  such as thalassemia major or sickle -
cell ana emia.
9.Clinically  significant uncompensated hearing loss in the judgment of the investigator. 
Use of hearing aids is allowed.
10.Any suicidal behaviour in the past 2 y ears (i.e. actual attempt, interrupted attempt, 
aborted attempt, or preparatory  acts or behaviour).
11.Any suicidal ideation of type [ADDRESS_424035] 3 months (i.e. active 
suicidal thought with intent but without specific plan, or active suicidal thought with 
plan and intent).
12.Known history  of HIV infection.
13.Significant history  of drug dependence or abuse (including alcohol, as defined in 
Diagnostic and Statistical Manual of Mental Disorders [DSM-V] or in the opi[INVESTIGATOR_342332]) within the last two y ears.
14.Previous participation in investigational d rug studies of dementia of Alzheimer’s Ty pe
within three months prior to screening. Patients h aving received any active treatment 
in stud iestargeting disease modification of AD are excluded. Previous participation 
in studies with non- prescription medicati ons, vitamins other nutritional formulations or 
non-pharmacological treatments is allowed.
15.Treatment with restricted medication (refer to Table [IP_ADDRESS] :1) prior to Visit 1 and/or 
during the screening period.
16.Planned electiv e surgery  requiring general anaesthesia, or hospi[INVESTIGATOR_130592] 
1day (requiring an overnight stay ) during the study  period.
17.For females: Women who a re of child bearing potential. Women not of childbearing 
potential are defined as: Women who are postmenopausal (12 months with no menses 
without an alternative medical cause) or who are permanentl y sterilized ( e.g. 
hysterectom y, bilateral oophorectom y or bilateral salpi[INVESTIGATOR_1656]).
For male s: Men who are able to father a child, unwilling to be abstinent or to use an 
adequate form of effective contraception for the duration of study participation and for 
at least 28 day s after treatment has ended.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 22of 77
Proprietary confidential information © [ADDRESS_424036]-03(12.0)/Saved on:30Jan201518.Indication of liver disease, defined b y serum levels of either ALT (SGPT), AST 
(SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined 
during screening .
3.3.4 Removal of patients from therapy or assessments
Removal of individual patients [IP_ADDRESS]
It is important to distinguish between premature study  drug discontinuation and premature 
study  discontinuation. 
Patients can stop taking study  drug for various reasons as described below; however, they  
should be encouraged to re
-start study  medication at the Investigator’ s discreti
on when he/she 
considers it safe to do so.
After premature stud y drug discontinuation patients should be asked to further attend 
scheduled trial visits, follow- up visits and assessments until the end of the trial unless they  
withdraw consent to participat e in the study . Should it not be possible to attend all visits, at 
least phone contacts should occur at the scheduled visit time points. It is vital to explain to
these patients the importance to continue trial participation.
Every  effort should be made t o collect data in all patients randomis ed. This includes 
randomised patients who never take study  medications and patients that prematurely  
discontinue study  drug.
Procedures to be followed for patients prematurely  terminating the study  drug and refusing to 
attend further trial visits are detailed in Section 6.2.3. Patients that withdraw from trial 
participation or study  drug will not be re placed. The data for patients who discontinue trial 
treatment or completel y withdraw from the trial after randomization must be documented and 
the reason for withdrawal and the date of last dose of study  drug must be recorded in the 
(e)CRF. These data must be included in the trial database and must be reported.
An individual patient is to be discontinued from study  drug if the following occurs:
The patient withdr aws consent for study  treatment , without the need to justify  the 
decision.
The patient needs to take concomitant drugs that interfere with the investigational 
product or other trial medication (see Section 4.2.2 for details) .
In the opi[INVESTIGATOR_689], continuation on the study  drug is not in the patient’s 
best i nterest, or if the patient fails to comply  with the protocol (e.g. non -attendance at 
trial assessments, and reason to be recorded in the electronic eCRF)
The patient can no longer be treated with trial medication for other medical reasons 
(such as surgery ,adverse events, other diseases, or pregnancy )
The patient’s disease/s and/or any  concomitant condition significantly worsens, in 
clinical judgement of the Investigator
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 23of 77
Proprietary confidential information © [ADDRESS_424037]-03(12.0)/Saved on:30Jan2015The patient exhibits serious suicidality , in the clinical judgment of the investigator or 
accor ding to the following criteria:
Any suicidal behaviour (i.e. actual attempt, interrupted attempt, aborted attempt, or 
preparatory  acts or behaviour)
Any suicidal ideation of type 4 or 5 in the C -SSRS (i.e. active suicidal thought with 
intent but wi thout specific plan, or active suicidal thought with plan and intent)
Patient non -compliance with study  drug administration (per Section 4.3 )
Patient is unblinded to treatment by [CONTACT_6624]
Decision b y Boehringer Ingelheim to disco ntinue a specific patient (e.g. in case of 
SAEs).
If a patient becomes pregnant or a pregnancy  is suspected during the trial the investigational 
drug will be stopped, the patient will be discontinued from treatment and the patient will be 
followed up thro ugh the end of the trial and until birth or otherwise termination of the 
pregnancy . For further information, including the process for follow -up on the outcome of the 
pregnancy  please see Section 5. 3.7.
Given the patient’s agreement, the patient will undergo the procedures for earl y treatment 
discontinuation and follow up as outlined in the Flow Chart and Section 6.2.3 .
For all patients the reason for withdrawal (e.g. adverse events) must be recorded in the 
(e
)CRF. These data will be included in the trial database and reported.
Discontinuation of the trial by  [CONTACT_941] s ponsor [IP_ADDRESS]
Boehringer Ingelheim reserves the right to discontinue the trial overall or at a particular trial 
site at any  time for the following reasons:
1. Failure to meet expected enrolment goals overall or at a particular trial site (this may  
include under -
recruitment or risk of over-recruitment towards the end of the recruitment 
period)
2.Emergence of an y efficacy /safet y information invalidating the earlier positive benefit -
risk-assessment that could significantl y affect the continuation of the trial
3. Violation of GCP, the CTP, or the contract disturbing the a ppropriate conduct of the trial
The Investigator / the trial site will be reimbursed for reasonable expenses incurred in case of 
trial termination (except in case of the third reas on).
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 24of 77
Proprietary confidential information © [ADDRESS_424038]-03(12.0)/Saved on:30Jan20154. TREATMENTS
TREATMENTS TO BE ADM INISTERED 4.1
Table 4.1: 1 Treatment groups
Group Treatment Regimen Treatment tbl./d
[ADDRESS_424039] (s)and comparator product(s)
Table 4.1.1: 1 BI 425809, 2mg:
Substance: BI425809
Pharmaceutical formulation: Table t
Source: Boehringer Ingelheim Pharma GmbH & Co KG
Birkendorfer Strasse 65
D-[ZIP_CODE] Biberach a.d. R iss
Unit strength: 1mg 
Daily  Dose 2 mg QD (2-0- 0) in Treatment Group 1
Posology QD
Route of administration: Per os
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 25of 77
Proprietary confidential information © [ADDRESS_424040]-03(12.0)/Saved on:30Jan2015Table 4.1.1: 2 BI 425809, 5mg :
Substance: BI425809
Source: Boehringer Ingelheim Pharma GmbH & Co KG
Birkendorfer Strasse 65
D-[ZIP_CODE] Biberach a.d. R iss
Unit strength: 5mg 
Daily  Dose 5 mg QD (1-0- 0) in Treatment Group 2
10 mg QD (2-0- 0) in Treatment Group 3
Posology QD
Route of administration: Per os
Table 4.1.1: 3 BI 425809, 25mg :
Substance: BI 425809
Pharmaceutical formulation: Tablet
Source: Boehringer Ingelheim Pharma GmbH & Co KG
Birkendorfer Strasse 65
D-[ZIP_CODE] Biberach a.d. Riss
Daily  Dose 25 m g QD (1 -0-0) in Treatment Group 4
Unit strength: 25mg
Posology QD
Route of administration: Per os
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 26of 77
Proprietary confidential information © [ADDRESS_424041]-03(12.0)/Saved on:30Jan2015Table 4.1.1: 4 Placebo matching BI 425809, 1mg and 5mg :
Substance: Placebo matching BI 425809
Pharmaceutical formulation: Table t
Source: Boehringer Ingelheim Pharma GmbH & Co KG
Birkendorfer Strasse 65
D-[ZIP_CODE] Biberach a.d. R iss
Unit strength: n.a.
Daily  Dose n.a.
Posology QD
Route of administration: Per os
Table 4.1.1: 5 Placebo matching BI 425809, 25mg :
Substance: Placebo matching BI 425809
Pharmaceutical formulation: Table t
Source: Boehringer Ingelheim Pharma GmbH & Co KG
Birkendorfer Strasse 65
D-[ZIP_CODE] Biberach a.d. R iss
Unit strength: n.a.
Daily  Dose n.a.
Posology QD
Route of administration: Per os
4.1.2 Method of assigning patients to treatment groups
Patients are randomi sedto treatment groups at Visit 2. Note that the medication number is 
different from the patient number (the latter is assigned at trial entry ). 
During Visit 2 and after the patient ’seligibility  has been confirmed
, the treatment will be 
assign edvia Interactive Response Technology  (IRT) . To facilitate the use of the IRT, the 
Investigator will receive all necessary  instructions .
4.1.3 Selection of doses in the trial
Efficacy  in animal cogni tion tests is shown at doses that produce approximately 50% gl ycine 
increase in cerebrospi[INVESTIGATOR_872] (CSF)
. These doses also result in CSF levels of BI 425809 of 
1x GLYT1 IC50. 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 27of 77
Proprietary confidential information © [ADDRESS_424042]-03(12.0)/Saved on:30Jan2015In a clinical phase I stud y(1346.3) [ c03724403- 01] a mean 50% gly cine increase in CSF was 
achieved at a dose of 10mg QD. 
A mean CSF concentration of BI 425809 of 1xGLTY1 I C50 (5nM) was achieved at a dose of 
[ADDRESS_424043] bo to be taken 
in the morning depending on the treatment arm. This will not be changed during the entire 
study  period (V2- EOT). 
For day s without site visits, patients should be instructed to take the tablets orally  with water 
in the morning at approximately  the same time every  day with or without food. If a dose is 
missed by  [CONTACT_726] 12hrs, that dose should be skipped and the next dose should be taken as 
scheduled. No double doses should be taken and dose reductions are not permitted. Patien ts 
should be instructed to bring all unused drug and empty  study  blister / bottles to the study  
site.
Patients should be instructed NOT to take their study  medication on the morning of scheduled 
trial visits. The first dose of study
 medication will be take n in the end of visit 2 under 
supervision of the investigator or site staff. At all site visits the morning dose of the 
investigational drug will be taken during the visit under supervision of the investigator or 
relevant site staff after (if applicable ) the blood samples were taken, the only exceptions are 
visits [ADDRESS_424044] dose of study 
medication will be taken at EOT/ED visit (i.e. end of randomized treatment visit) .
The actual visit date and time of study drug administration at the trial visit will be recorded 
in the eCRF at each visit. Patients are allowed to have a light breakfast/meal before the 
scheduled visit. Patients who erroneously  take the morning dose of study  medication before 
coming to the clin ic at a visit with scheduled PK samples should have the visit rescheduled as 
soon as possible, ideally  on the following day .
4.1.5 Blinding and procedures for unblinding
Blinding [IP_ADDRESS]
Patients, Investigator s and every one involved in trial conduct or analy sisor with an y other
interest in this double -blind trialwill remain blinded with regard to the randomised treatment 
assignments until after database lock.
The randomization code will be kept secret by  [CONTACT_342345].
The randomization codes will be provided to bioanaly tics prior to last patient out to allow for 
theexclusion from the analyses of pharmacokinetic ( PK) samples taken from placebo 
patients. Bioanal ytics will not disclose the randomization code or the results of their 
measurements until the trialis officially  unblinded.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 28of 77
Proprietary confidential information © [ADDRESS_424045]-03(12.0)/Saved on:30Jan2015Unblinding and breaking the code [IP_ADDRESS]
Emergency  unblinding will be available to the Investigator / Pharmacist / investigational drug 
storage manager via IRT. It must only  be used in an emergency  situation when the identity  of 
the trial drug must be known to the Investigator in order to provide appropriate medical 
treatment or otherwise assure safety  
of trial participants. The reason for unblinding must be 
documented in the source documents and/or appropriate CRF page along with the date and 
the initials of the person who broke the code.
Due to the requirements to report Suspected Unexpected Serious A dverse Reactions 
(S[LOCATION_003]Rs), it may  be necessary  for a representative from Boehringer Ingelheim’s 
Pharmacovigilance group to access the randomisation code for individual patients during trial 
conduct. The access to the code will onl y be given to authorised P harmacovigilance 
representatives and not be shared further.
For Japan only : In 
this blinded trial, an emergency code break will be available tothe 
Investigator / the sub- Investigator s via the IRT s ystem. This code break may  only  be accessed 
in emergency  situations when the identity  of the trial drug must be known to the Investigator
/the sub- Investigator s in order to provide appropriate medical treatment or if required to 
assure the safet y of trial participants. Each site receives a manual from the IRTprovider that 
contains instructions on how to unblind the treatment of a patient via the IRT(via 24 -hour 
Emergency  helpline ). If the code break for a patient is accessed, th e Sponsor must be 
informed immediately. The reason for accessing the code break, together with the date, must 
be documented on the appropriate eCRF page. In case third party  needs to break the code, 
however, when the Investigator cannot be reached, the cod e can be opened by  [CONTACT_342346].
4.1.[ADDRESS_424046] be maintained for documentation.
If the storage conditions are found to be outside the specified range, the local clinical monitor 
(as provided in the list of contacts) must be contact[CONTACT_15608] .
4.1.8 Drug accountability
The Investigator / Pharmacist / investigational drug storage manager will receive the 
investigational drugs delivered b y the Sponsor when the following requirements are fulfilled:
Approval of the trial protocol by  [CONTACT_1201] / ethics committee, 
Availability  of a signed and dated clinical trial contract between the Sponsor and the 
head of the investigational site ,
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 29of 77
Proprietary confidential information © [ADDRESS_424047]-03(12.0)/Saved on:30Jan2015Approval/notification of the regulatory  authority , e.g. competent authorit y,
Availability  of the curriculum vitae of the principal Investigator ,
Availability  of a signed and dated clinical trial protocol
Availability  of the proof of a medical license for the principal Investigator
for [LOCATION_003] a vailabilit y of Form 1572
The Investigator / Pharmacist 
/ investigational drug storage manager must maintain records of 
the product’s delivery  to the trial site, the inventory  at the site, the use by  [CONTACT_6904], and 
the return to the Sponsor or alternative dispos al of unused products. 
These records will incl ude dates, quantities, batch / serial numbers, expi[INVESTIGATOR_4061]  (‘use -by’) dates, 
and the unique code numbers assigned to the investigational product and trial patients. The 
Investigator / Pharmacist / investigational drug storage manager will maintain records that
document adequately that the patients were provided the doses specified b y the CTP and 
reconcile all investigational products received from the Sponsor . At the time of return to the 
Sponsor / appointed CRO, the Investigator / Pharmacist / investigational drug storage 
manager must verify  that all unused or partiall y used drug supplies have been returned b y the 
clinical trial patient and that no remaining supplies are in the Investigator ’s possession.
CONCOMITANT THERAPY, RESTRICTIONS, AND RE SCUE 4.2
TREATMENT
4.2.1 Rescue medication, emergency procedures, and additional treatment(s)
There are no special emergency  procedures to be followed.
4.2.2 Restrictions
Restrictions regarding concomitant treatment [IP_ADDRESS]
For any chronic concomitant treatments stable dose and treatment regime should be 
maintained whenever possible during patient’s participation in the trial. In particular 
this would apply for antihypertensive drugs, lipid -
lowering drugs, antidiabetic drugs 
and prot on pump inhibitors .
Refer to Table [IP_ADDRESS]
:1for relevant washout periods prior to cognitive testing during the 
study .
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 30of 77
Proprietary confidential information © [ADDRESS_424048]-03(12.0)/Saved on:30Jan2015Table [IP_ADDRESS]:1 Provides an overview of required, permitted and restricted medication. 
Study Period
Drug class Sub- class Prior to Visit 1 Visit 1 and 
Screening 
PeriodTreatm ent 
PeriodFollow -up 
Period
AD treatments Cholinesterase 
inhibitors: eg 
Donepezil, 
rivastigmin, 
galantamine, 
tacrine, 
phenserinePerm itted if 
initiated and 
stable for at least 
3 months prior to 
Visit 1 and no 
change is 
foreseen during 
the studyPerm itted if 
no dose and/or 
treatment 
regime changePerm itted if 
no dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
memantine NOT permitted 
for at least 3 
months prior to 
Visit 1NOT 
permittedNOT 
permittedNOT 
permitted
Hypnotics/Sedatives Benzodiazepi[INVESTIGATOR_342333] 
(eg H 1inhibitors, 
melatonine, 
herbal products 
etc.)1Perm itted if 
stable 8 w eeks 
prior to V1Perm itted if 
no dose and/or 
treatment 
regime changePerm itted if 
no dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Barbiturates NOT permitted 
for at least 3 
months prior to 
Visit 1NOT 
permittedNOT 
permittedNOT 
permitted
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 31of 77
Proprietary confidential information © [ADDRESS_424049]-03(12.0)/Saved on:30Jan2015Table [IP_ADDRESS]:1 Provides an overview of required, permitted and restricted medication. (cont.)
Study Period
Drug class Sub- class Prior to Visit 1 Visit 1 and 
Screening 
PeriodTreatm ent 
PeriodFollow -up 
Period
Antipsychotics 
(Neuroleptics)Typi[INVESTIGATOR_2855] (1st
generation) and 
Atypi[INVESTIGATOR_2855] (2nd
generation)
Antipsychotics1Perm itted if stable 
at least 8 w eeks 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Antidepressants Tricyclic, 
Tetracyclic, 
MAO inhibitors, 
SSRI, SNRI, 
SMSs, SARIS, 
NaSSA, NRIs  
and other 
mechanisms of 
action including 
herbal products1Perm itted if stable 
at least 8 w eeks 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Nootropi[INVESTIGATOR_1102]/       
Cognitive 
enhancers 
including 
Gingko and 
peripheral 
vasodilators Miscellaneous1Perm itted if 
initiated at least at 
Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Psychostimulants 
and 
PsychodyslecticsMiscellaneous1Perm itted if stable 
at least 3 months 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Antiepi[INVESTIGATOR_342334] 3 months 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 32of 77
Proprietary confidential information © [ADDRESS_424050]-03(12.0)/Saved on:30Jan2015Table [IP_ADDRESS]:1 Provides an overview of required, permitted and restricted medication. (cont.)
Study Period
Drug class Sub- class Prior to Visit 1 Visit 1 and 
Screening 
PeriodTreatm ent 
PeriodFollow -up 
Period
Antiparkinsonics Any 
Dopaminergics
and/or MAO -B 
inhibitors and/or 
COMT Inhibitors 
and/or 
Anticholinergics 
including 
Antihistaminines 
with 
anticholinergic 
effect Perm itted if stable 
at least 3 months 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Muscle relaxants Central1Perm itted if stable 
at least 8 w eeks 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Antiemetics Antihistamines, 
Benzamides, [ADDRESS_424051] 8 w eeks 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Antimuscarinic 
drugs used for 
urinary 
incontinence 
treatment1Perm itted if stable 
at least 4 w eeks 
prior to Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Central 
AnalgesicsOpi[INVESTIGATOR_74453]1Perm itted if 
stable at least 4 
weeks prior to 
Visit 1Perm itted if no 
dose and/or 
treatment 
regime changePerm itted if no 
dose and/or 
treatment 
regime changePerm itted if 
no dose 
and/or 
treatment 
regime 
change
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 33of 77
Proprietary confidential information © [ADDRESS_424052]-03(12.0)/Saved on:30Jan2015Table [IP_ADDRESS]:1 Provides an overview of required, permitted and restricted medication. (cont.)
Study Period
Drug class Sub- class Prior to Visit [ADDRESS_424053] 8 
weeks prior to 
Visit 1NOT permitted NOT permitted NOT 
permitted
CYP3A4 
sensitive drugs 
with narrow  
therapeutic 
index (e .g.
cyclosporine, 
fentanyl)2,[ADDRESS_424054]. 
John’s wort 
preparationsNOT permitted 
for at least 7 
days prior to 
Visit 2NOT 
permittedNOT
permittedNOT 
permitted
Vitamin 
B12/FolatePerm itted in case 
of stable 
treatm ent prior 
to V1 or even if 
initiated either at 
Visit 1 or during 
screening periodPerm itted Perm itted Perm itted
Nutritional 
Support of ADPerm itted in case 
of stable 
treatm ent prior 
to V1 or even if 
initiated either at 
Visit 1 or during 
screening periodPerm itted if 
no dose and/or 
treatm ent 
regim e changePerm itted if 
no dose and/or 
treatm ent 
regim e changePerm itted if 
no dose 
and/or 
treatm ent 
regim e 
change
Investigational 
Drugs NOT permitted 
for at least 3 
months or 6 half -
lives (whatever 
comes longer) 
prior to Visit 1NOT permitted NOT permitted NOT 
permitted
1If these drugs are taken occasionally, i.e. on as needed bases, or if such treatment needs to be added and/or dose changed 
then dosing on the night prior to cognitive testing is not allowed. 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 34of 77
Proprietary confidential information © [ADDRESS_424055]-03(12.0)/Saved on:30Jan20152For medication list, refer to the ISF
3If any of the listed dru gs need to be added, then the IMP should be discontinued for at least the period of needed concurrent 
use. Once the us e of either strong/moderate CYP3A4 inhibitors and inducers or CYP3A4 sensitive drugs with narrow 
therapeutic index is stopped, the re -introduction of the trial drug is possible as per investigator clinical judgement. The 
re-introduction details may be consulted with the clinical monitor local.
Please note: C YP3A4and C YP2B6 sensitive drugs may have decreased levels of exposure 
when given concomitantly with BI 425809. Investigators should assess if dose adjustments 
and/
or monitoring of the underlying disease is clinically required for patients who are taking 
such drugs. For a
list of CYP3A4 and C YP2B6 sensitive drugs please refer to the list in the
ISF. 
BI 425809 may cause clinically relevant induction of CYP2B6. CYP2B6 sensitive drugs are 
not excluded but are to be given with caution. 
Restrictions on diet and life sty le [IP_ADDRESS]
There are no other restrictions on diet, exercise, alcohol consume or smoking except that the 
patient’s usual habits, including nicotine and caffeine intake, should be within acceptable 
daily  amounts in discretion of the investigator and not be drasticall y changed throughout the 
study  conduct. The use of grapefruit juice (strong C YP3A4 inhibitor) and St. John’s 
wort preparations (strong CYP3A4 inducer) are restricted (see list of C YP3A4 
inhibitors in the ISF)
starting [ADDRESS_424056] the assessment of cognitive tests and 
therefore may be used only in line with Table [IP_ADDRESS]:[ADDRESS_424057] been taken according to the scheduled 
period, multiplied by  100. Complian ce will be verified by  [CONTACT_21639]-sitemonitor authorised b y 
the Sponsor.
Treatment compliance (%) =Number of tablets actually  taken [ADDRESS_424058] been taken
If the number of doses taken is not between 80 -120% , site staff will explain the patient the 
importance of treatment compliance.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 35of 77
Proprietary confidential information © [ADDRESS_424059]-03(12.0)/Saved on:30Jan20155. VARIABLES AND THEIR ASSESSMENT 
TRIAL ENDPOINTS 5.1
The following efficacy measures are completed at the times shown in Section 6.2 and the 
Flow C hart:
5.1.1 Primary Endpoint (s)
The change from baseline in ADAS -Cog 11(Alzhei mer’s Disease Assessment Scale-
Cognitive subscale 11 item
) total score after 12 weeks of
treatment
5.1.2 Secondary Endpoint(s)
Change from baseline in the ADCS -ADL (Alzheimer’s Disease Cooperative 
Study /Activities of Dail y Living) score after 12week s oftreatment
CIBIC+ (Clinician's Interview -Based Impression of Change )score after 1 2 week s of
treatment
ASSESSMENT OF EFFICA CY 5.2
Established neuropsychological assessments will be used to capture individual changes in 
memory , cognitive function and activities of dail y living. Detailed instructions how to 
administer the assessments can be found in the respective user manuals which will be filed in 
the ISF.
ADAS -Cog 11is an 11- item cognitive subscale that objectively  measures memory , language, 
orienta tion and praxis wit h a total score range of 0 to 70, with lower scores indicating less 
severe impairment.  A negative change indicates an improvement from baseline [R96-2608
].

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 36of 77
Proprietary confidential information © [ADDRESS_424060]-03(12.0)/Saved on:30Jan2015ADCS -ADL is a rating scale used to assess basic and instrumental activities of daily  living. 
In the full version of the scale, 23 items are rated by [CONTACT_342347]. Each item has a score range vary ing from 0 -3 to 0 -5. The sum 
score could range from 0 to 78, with higher scores indicat ing less severe impairment.  A 
positive change indicates an improvement from baseline [R97-
3207].
CIBI S and CIBI C+ (Clinician's Interview -Based Impression of Change) scales are based on 
semi -structured interview covering domains of f unction and cognition. They  additionally  
require the assessment of psy chiatric signs and s ymptoms.  T he patient and their caregiver are 
interviewed and questioned by [CONTACT_15370] [R17-3992].  

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 37of 77
Proprietary confidential information © [ADDRESS_424061]-03(12.0)/Saved on:30Jan2015ASSESSMENT OF S AFETY 5.3
5.3.1 Physical examination
A full phy sical examination will be performed at the visits indicated in the Flow C hart. This 
should be performed according to medical standards and usually  includes (but is not 
necessarily  limited to) a review of the following organ s ystems: Gen eral appearance 
(including Skin), Head -Eyes-Ears-Nose -Throat (HEENT), Chest (including Pulmonary  and 
Heart), Abdomen, Extremities, Urogenital  and neurological assessment (basic mental status, 
cranial nerves, motor s ystem, sensation, cerebellum/coordinatio n). Clinically relevant 
abnormal findings documented after inclusion will be reported as (S)AEs.
5.3.2 Vital Signs
Systolic and diastolic blood pressure (BP) and pulse rate (PR) will be measured after the 
patient has rested for at least [ADDRESS_424062] are listed in Table 5.3.3: 1 and 
Table 5.3.3: 2 . All anal yses will be performed b y a central laboratory. Patients don’t have to 
be fasted for the blood sampling for the safet y laboratory . The respective reference ranges 
and details about sample handling and sh ipment will be provided in the I SF (Lab Manual).
Haemoglobin, GFR, ALT, AST and alkaline phosphatase found abnormal at Visit 1 
may be re -tested twice prior to Visit 2.
The following lab parameters will not be determined at each study  visit:
TSH at screening onl y
Vitamin B12 and folate at screening and EOT only ; if atScreening visit (Visit 1) 
Vitamin B12 and folate 
lab results are found abnormal (below lower limit normal) an 
appropriate treatment may be initiated. Two re-testscanbe done prior to Visit 2. The 
patient can be randomis ed only  if Vitamin B12 and folate lab results are within 
normal reference ranges. Refer to section 6.1 for further information on visit 
scheduling. 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 38of 77
Proprietary confidential information © [ADDRESS_424063]-03(12.0)/Saved on:30Jan2015Table 5.3.3: 1 Safety  laboratory  parameter s –whole blood, serum or plasma
Hematology
Haematocrit
Haemoglobin
MCV, MCH, RDW, MCHC
Reticulocy te Count and Index
(reflex test if Hb outside normal 
range or decreased >2g/dL 
compared to baseline )
Red Blood Cells (RBC) / 
Erythrocy tesWBC / L eukocy tes
Platelet Count / Thrombocy tes
Differential Automatic (relative and 
absolute count): 
Neutrophils, Eosinophils, Basophils, 
Monocy tes,  Ly mphocy tes
Clinical chemistry
Albumin 
Alkaline phosphatase
--GT (gamma -glutam yl 
transferase) reflex test triggered b y
elevated alkaline phosphatase on 
two sequential measures
ALT (alanine aminotransaminase, 
SGPT)
AST (aspartate 
aminotransaminase, SGOT) 
Bicarbonate
Bilirubin total, fractionated if 
increased 
Calcium 
Chloride 
Creatinine 
Vitamin B12
Ferritin, serum iron, transferrin 
and TIBC as reflex if Hb outside 
normal range or decreased >2g/dL 
compared to baselineCreatine kinase (CK)
CK-MB, troponin (reflex tests if CK is 
elevated)
Lactate deh ydrogenase (LDH)
Lipase
Magnesium 
Phosphate 
Potassium
Protein total 
Sodium
Urea (BUN)
LDL/HDL and total cholesterol
Trigl ycerides
TSH
Folate
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 39of 77
Proprietary confidential information © [ADDRESS_424064]-03(12.0)/Saved on:30Jan2015Table 5.3.3: 2 Safety  laboratory  parameters –urine
Urinalysis 
Semi quantitative
Nitrite
Protein
Glucose
Hemoglobin
Ketone
Urine pH
Leukocy te esterase (for 
WBC)
Urine Drug Screen
Cannabis 
Cocaine
Benzodiazepi[INVESTIGATOR_050]
Amphetamines
Barbiturates
Methadone
Opi[INVESTIGATOR_858]
Phency clidine (PCP)
Human urine chorionic 
gonadotropin (HCG)*
*Pregnancy testing (HCG, urine) will only be performed if required by [CONTACT_427] . It may also be done more
frequently or in plasma instead of urine if required (please note: this trial will include no patients of child -bearing 
potential)
5.3.4 Electrocardiogram
A12- lead ECGs (I , II, III, aVR, aVL, aVF, V1 – V6) will be performed as scheduled in the 
Flow Chart using the equipment provided by  [CONTACT_342348]. The ECGs will be 
recorded for at least [ADDRESS_424065] 5 minutes in 
a supi[INVESTIGATOR_2547]. Electrode placement will be performed according to the method of 
Einthoven/Goldberger (ankles and wrists). Single ECGs will be recorded at the time points 
indicated in the Flow Chart.  At visits 3, [ADDRESS_424066] I MP dosing to correlate with the c maxof the BI 425809. ECG 
recordings at planned time points may  be repeated for quality  reasons like alternating current 
artefacts, muscle movements and electrode dislocation. I n this case the repeated ECG 
recordings will be used if quality  was better.
The investigator or a designee should evaluate whether the ECG is normal or abnormal and 
whether it is clinically significant, if abnormal. The electronic version of the ECG is regarded 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 40of 77
Proprietary confidential information © [ADDRESS_424067]-03(12.0)/Saved on:30Jan2015as source data. Dated and signed printouts will be stored in the patient’s medical file if there 
is no validate d and certified e -medical record for ECG data.
Additional ECGs may be collected b y the investigator for safet y reasons. Clinically  relevant 
findings noticed at baseline assessment should be reported as baseline condition .Clinically  
relevant abnormal find ings noticed after baseline assessment will be reported as adverse 
events and followed up and/or treated locally until normal or stable condition.
All ECGs will be transmitted electronically  to the central ECG vendor to perform a 
centralized and independent anal ysis. Abnormalities detected during this centralized ECG 
evaluation will not necessarily  qualify  as AEs.
Central evaluation on individual ECGs will be performed b y the vendor and a report will be 
provided to the site . Decisions on patient’s eligibility , treatment or further follow -up of an y 
ECG related findings are the responsibility  of the investigator . 
5.3.5
Other safety parameters
Suicidal risk assessed by [CONTACT_941] C- SSRS [IP_ADDRESS]
Consistent with the FDA draft guidance entitled "Suicidal I deation and Behavio ur: 
Prospective Assessment of Occurrence in Clinical Trials", prospective assessment of suicidal 
ideation and behaviour is included in this study  using the C -SSRS (paper version; shall be 
administered via Bracket rater -station) . 
The C -SSRS is a semi -structured, investigator -rated interview, developed by  [CONTACT_342349], assessing both suicidal behaviour and suicidal ideation. I t does 
not give a global score, but provides some categorical and some severity  infor mation 
specificall y for behaviour and ideation.
The C -SSRS interview may  be administered by  [CONTACT_342350], ps ychologist, clinical 
social worker, mental health counsellor, nurse, or coordinator with C -SSRS training. It has a 
typi[INVESTIGATOR_342335], and causes onl y a low burden on subjects. At a minimum, 
the interview consists of 2 screening questions related to suicidal ideation and 4 related to 
suicidal behaviour, and may  be expanded to up to 17 items in case of positive responses. Free 
text entries are allowed for; the investigator has to directly  evaluate the scale and write a 
report.
The C -SSRS has been widely  used in large multinational clinical trials. The C -SSRS will be 
administered at the screening visit (using the ‘screening / basel ine’ version) with the aim to 
exclude subjects with active moderate or severe s ymptomatology within a specified time 
prior to the screening or baseline visit. The life time history  of suicidal ideation and 
behaviour will also be recorded.
After the baselin e visit the assessment ‘since last visit’ will be performed at each clinic or 
phone visit (‘since last visit’ version). The investigator is to review positive and negative 
reports for plausibility and clinical relevance. Doubtful reports may  be repeated or reports 
may be validated by  a consulting psy chiatrist. If there is a confirmed positive report of 
suicidal behaviour or suicidal ideation type [ADDRESS_424068] during the clinic visit, a nd/or is to consult a psy chiatrist. If 
the positive report is confirmed, appropriate actions for the subject’s safet y have to be 
initiated.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 41of 77
Proprietary confidential information © [ADDRESS_424069]-03(12.0)/Saved on:30Jan2015All C -SSRS reports of suicidal ideation type [ADDRESS_424070] 
be reported as separate SAEs by  [CONTACT_093]. 
For ‘Self -injurious behaviour, no suicidal intent’ (Ty pe 11) standard AE / SAE reporting 
rules are to be applied.
For each negative report (suicidal ideation ty pe 1, 2 or 3) after start of the trial, the 
investigator is to decide based on clinical judgment whether it represents an adverse event 
(AE) as defined in the protocol, and if it is considered an AE then it must be reported 
accordingl y.
5.3.6 Assessment of adverse events
Definitions of AEs [IP_ADDRESS]
Adverse event
An adverse event (AE) is defined as a ny untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily  have 
to have a causal re lationship with this treatment.
An AE can therefore be any  unfavourable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.
Adverse reac tion
An adverse reaction is defined as a response to a medicinal product which is noxious and 
unintended. Response in this context means that a causal relationship between a medicinal 
product and an adverse event is at least a reasonable possibility . Adver se reactions may  arise 
from use of the product within or outside the terms of the marketing authorisati
on or from 
occupational exposure. Conditions of use outside the marketing authorization include off 
label use, overdose, misuse, abuse and medication err ors.
Serious adverse event
A serious adverse event (SAE) is defined as any AE which:
results in death,
is life -threatening,
requires inpatient hospi[INVESTIGATOR_36118],
results in persistent or signif icant disability  or incapacity ,
is a c ongenital anomal y/birth defect,
or
is to be deemed serious for an y other reason if it is an important medical event when 
based upon appropriate medical judgment which may  jeopardize the patient and may  
require medical or surgical interven tion to prevent one of the other outcomes listed in 
the above definitions.
Life-threatening in this context refers to an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event that hy pothetically  might ha ve caused death 
if more severe. All reports of suicidal ideation ty pe 4 or 5 and all reports of suicidal behavior 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 42of 77
Proprietary confidential information © [ADDRESS_424071]-03(12.0)/Saved on:30Jan2015from prospe ctive monitoring in C -SSRS (see S ection [IP_ADDRESS] for details) are also considered 
to be life- threatening and must be reported as SAEs by  [CONTACT_093].
For Japan only : The following events will be handled as “deemed serious for any  other 
reason”. An AE which possibly  leads to disability will be reported as an SAE.
AEs considered “Always Serious”
In accordance with the European Medicines Agency initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of AEs, which by  [CONTACT_15623], can alway s be 
considered to be “serious” even though they  may  not have met the crite ria of an SAE as given 
above.
The latest list of “Alway s Serious AEs” can be found in the RDC . These events should 
alway s be reported as SAEs as described in Section 5.3.7.
Cancers of new histology and exacerbations of existing cancer must be reported as a serious 
event regardless of the duration between discontinuation of the drug and the occurrence of the 
cancer.
Adverse events of special interest (AESIs)
The term AESI relates to any  specific AE that has been identified at the project level as being 
of particular concern for prospective safet y monitoring and safet y assessment within this trial, 
e.g. the potential for AEs based on knowledge from other compou nds in the same class. AESI 
need to be reported to the Sponsor’s Pharmacovigilance Department within the same 
timeframe that applies to SAE, see Section 5.3.7.
The following are considered as AESIs:
Hepatic injury
A hepatic injury  is defined by  [CONTACT_15624]: 
an elevation of AST and/or ALT >[ADDRESS_424072] combined with an elevation of total 
bilirubin >[ADDRESS_424073] measured in the same blood draw sample, and/or
marked peak aminotransferase (ALT, and/or AST) elevations ≥[ADDRESS_424074]
These lab findings constitute a hepatic injury alert and the patients showing these lab 
abnormalities need to be followed up according to the “DILI checklist” provided via the 
RDC -system.
In case of clinical s ymptoms of hepatic injury  (icterus, unexplained encephalopathy , 
unexplained coagulopathy , right upper quadrant abdominal pain, etc.) without lab results 
(ALT, AST, total bilirubin) available, the investigator should make sure these parameters are 
analysed, if necessary  in an unscheduled blood test. Should the results meet the criteria of 
hepatic injury  alert, the procedures described in the DILI checklist should be followed .
No further AESI s have been defined for this trial.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 43of 77
Proprietary confidential information © [ADDRESS_424075]-03(12.0)/Saved on:30Jan2015Intensity of AEs
The intensity  of the AE should be judged based on the following:
Mild: Awareness of sign(s) or sy mptom(s) that is/are easily  tolerated
Moderate: Enough discomfort to cause interference with usual activity
Severe: Incapacitating or causing inability  to work or to perform usual activities
Causal relationship of AEs
The definition of an adverse reaction implies at least a rea sonable possibility  of a causal 
relationship between a suspected medicinal product a nd an adverse event. An adverse 
reaction, in contrast to an adverse event, is characterised b y the fact that a causal relationship 
between a medicinal product and an occurrence is suspected.
Medical judgment should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship , de-challenge or re -challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant
history .
Arguments that may  suggest that there is a reasonable possi bility  of a caus al relationship 
could be:
The event is consistent with the known pharmacology  of the drug
The event is known to be caused b y or attributed to the drug class.
A plausible time to onset of the event relative to the time of drug exposure.
Evidence that the ev ent is reproducible when the drug is re -introduced
No medicall y sound alternative aetiologies that could expl ain the event (e.g. 
preexisting or concomitant diseases, or co -medications).
The event is t ypi[INVESTIGATOR_1306] y drug -related and infrequen t in the general popu lation not 
exposed to drugs (e.g. Stevens- Johnson sy ndrome).
An indication of dose -response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is diminished).
Arguments that may  suggest that there is no reasonable possi bility  of a causal relationship 
could be:
No plausible time to onset of the event relative to the time of drug exposure is evident
(e.g. pre -treatment cases, diagnosis of cancer or chronic disease within days / weeks of 
drug administration; an allergic reaction weeks after discontinuation of the drug
concerned)
Continuation of the event despi[INVESTIGATOR_15576], taking into 
account the pharmacological properties of the compound (e.g. after 5 half -lives).
Of note, this criterion may not be applicab le to events whose time course is prolonged
despi[INVESTIGATOR_15577].
Additional arguments amongst those stated before, lik e alternative explanation (e.g. 
situations where other drugs or underl ying diseases appear to provide a more likely  
expl
anation for the observed event than the drug concerned).
Disappearance of the event even though the study  drug treatment continues or remains 
unchanged.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 44of 77
Proprietary confidential information © [ADDRESS_424076]-03(12.0)/Saved on:30Jan2015For Japan only : the reason for the decision on causal relationship for unlisted AEs needs to be
provided in the CRF.
5.3.[ADDRESS_424077] be collected and documented on the appropriate eCRF by [CONTACT_3786]:
From signing the informed consent onwards through the Residual Effect 
Period 
(REP) , until individual patient’s end of trial:
-all AEs (serious and non -serious) and all AESI s.
After the individual patient’s end of trial: 
-the investigator does not need to activel y monitor the patient for AEs but should 
only report relevant SAEs and relevant AESIs of which the investigator may  become 
aware of.
Figure 5.3.7: 1  Collection and reporting of AEs/SAEs during the study
If a patient reports a change in visual perception or any  vision- related AE, site staff must 
record the patient’s verbatim description in the source documents to be reported in the eCRF
and SAE form, if applicable . A local ophthalmology  assessment will be required for any 
visual AE that is rated as moderate or severe b y the subject or at the discretion of the PI . The 
ophthalmologist will act as a consultant to the Investigator and may  offer a dvice on the 
proper management and treatment for the reaction.
The REP is defined as 11days after the last trial medication application. All AEs which 
occurred through the treatment phase and throughout the REP will be considered as on 
treatment please s ee Section 7.3.[ADDRESS_424078] treatment events.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 45of 77
Proprietary confidential information © [ADDRESS_424079]-03(12.0)/Saved on:30Jan2015AE reporting to sponsor and timelines
The Investigator must report SAEs, AESI s, and non -serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately  (within 24 hours ) to the 
Sponsor’s unique entry  point (country  specific contact [CONTACT_21644] I SF). 
The same timeline applies if follow-up information becomes available. In specific occasions 
the Investigator could inform the Sponsor upfront via telephone. This does not replace the 
requirement to complete and fax the BI SAE form.
For Japan only : All SAEs and AESI s must be reported immediately  to the head of the trial 
site.
With receipt of an y further information to these events, a follow -up SAE form has to be 
provided. For follow -up information the same rules and timeline apply  as for ini tial 
information.
Information required
For each AE, the Investigator should provide the information requested on the appropriate 
(e)CRF pages and the BI SAE form . The Investigator should determine the causal 
relationship to the trial medication .
The foll owing should also be recorded as an (S)AE in the (e)CRF and SAE form (if 
applicable):
Worsening of the underly ing disease or of other pre -existing conditions
Changes in vital signs, ECG, phy sical examination and laboratory  test results, if they  
are judged clinically  relevant by  [CONTACT_737].
If such abnormalities already  pre-exist prior trial inclusion they  will be considered as 
baseline conditions.
All (S)AEs, including those persisting after individual patient’s end of trial must be followed 
up until they  have resolved, have been sufficiently  characterized, or no further information 
can be obtained.
Pregnancy
In rare cases pregnancy  may  occur in a clinical trial. Once a patient has been enrolled into 
this clinical trial and has taken trial medication, the Inves tigator must report immediately  
(within 24 hours) a
nypotential drug exposure during pr egnancy  (DEDP) to the sponsor’s 
unique entry point (country -specific contact [CONTACT_15626]). The
Pregnancy  Monitoring Form for Clinical Trials (Part A) should be used.
The outcome of the pregnancy  associated with the drug ex posure during pregnancy  must be 
followed up and reported to the sponsor’s unique entry  point on the Pregnancy  Monitoring
Form for Clinical Tr ials (Part B).
The I SF will contain the Pregnancy  Monitoring Form for Clinical Trials (Part A and B).
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 46of 77
Proprietary confidential information © [ADDRESS_424080]-03(12.0)/Saved on:30Jan2015As pregnancy  itself is not to be reported as an AE, in the absence of an accompany ing SAE 
and/or AESI, onl y the Pregnancy Monitoring Form for Clini cal Tr ials and not the SAE form 
is to be completed. If there is an SAE and/or AESI associated with the pregnancy  an SAE 
form must be completed in addition.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 47of 77
Proprietary confidential information © [ADDRESS_424081]-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 48of 77
Proprietary confidential information © [ADDRESS_424082]-03(12.0)/Saved on:30Jan20156. INVESTIGATIONAL PLAN
VISIT SCHEDULE 6.1
All trial visits should be initiated preferentiall y in the morning starting before 9:[ADDRESS_424083] at the study  site under site staff supervision .
All patient visits should be scheduled according to the Flow Chart . 
All visit procedures 
should preferabl y be completed on one day. If necessary (preferred), all planned 
neurops ychological rating scales (as per Flow Chart ) from Visit 1 (screening ) to Visit 6 (end 
of treatment) can be performed one day  prior to the planned 
clinic visit. Sites should make 
every  attempt to adhere to the protocol time windows as close as possible. The screening 
period may be shorten to a minimum of 7 days if all screening procedures and results 
are available. At the same time thescreening period ( i.e. period between Visit 1 and Visit 
2) may be extended by  [CONTACT_168984] 4 
week s(i.e. 42 day s in total) for anyreason (e.g. 
administrative reasons, lab re -tests, concomitant medication adherence, adverse event, etc.) . 
If screening period needs to be extended any further, the clinical monitor should be contact[CONTACT_342351]. If any visit after the randomisation has to be rescheduled, subsequent 
visits should follow the original visit schedule with the goal to reach 85+[ADDRESS_424084] of the neurops ychological assessments need to be
followed: 
The assessments should be administered in the same sequence found in the flowchart 
and approximately at the same time of the day at every  applicable visit. 
Assessment of the Neuropsy chological Rating Scales should preferentially  be done by  
[CONTACT_342352] a given patient throughout the study  period.
CIBIS/CIBIC+ rater should not perform other ratings and further procedures such as 
laboratory  procedures, dispensing of IMP, or monitoring of AEs and ASEs. 
The study  
partner contributing to the functional assessments should not change during the study . 
If that cannot be avoided this is to be recorded in the source data and as a protocol 
violation. 
The members of the site staff performing the assessment have to be properly  trained (either at 
the investigator training or individually ) and training documentation has to be filed in the 
ISF. The training standards and standards for the conduct of the assessments will be defined 
for each assessment individually  and can be found in the I SF. It is the responsibility  of the 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 49of 77
Proprietary confidential information © [ADDRESS_424085]-03(12.0)/Saved on:30Jan2015Principal I nvestigator at the site to ensure proper training of all members of the site staff 
involved in the neurops ychological assessments.
6.2.1 S creening and run -in period(s)
Screening Period
Informed Consent prior to trial participation
All patients must sign an Informed Consent consistent with I CH-GCP guidelines prior to an y 
study  specific procedures. Please refer to Section 8.1 for details. 
Particular procedures
The screening visit (see Flow Chart for full details) will include the following 
procedures/assessments: check of signed Informed Consent, demographics, review of 
relevant medic al history /baseline conditions at the discretion of the Investigator, relevant 
medication history and review of concomitant therapy , inclusion/exclusion criteria, phy sical 
exam, body  weight and height, vital signs (blood pressure and pulse rate), ECG, safe ty 
laboratory  tests. Neuropsy chological assessments and suicidality  monitoring will be done.
6.2.2 Treatment period(s)
The procedures of the visits in the treatment phase will be performed as outlined in the Flow 
Chart . 
Visit 2 ( Baseline )
As soon as eligibility  of a screened patient is confirmed, the patient may enter the study  and 
Visit [ADDRESS_424086] been successfull y 
completed and eligibility has been confirmed (including results of the neuropsy chological 
rating scales performed at Visit 1). 
Neurops ychological assessments will be done. Similarly  suicidality  monitoring shall be 
performed and eligibility criteria shall be re -assessed.
Study  medication should be taken at the end of the visit at the site and study drug kits will be 
dispensed for home administration. Intake of study  drug and handling of the blisters needs to 
be trained with the patient and the study  partner.
Visit 3a
This visit will be a mandatory  clinic visit . Study  procedures have to be completed according 
to the Flow Chart.
Visit 3b and 3c :
These visits may  be phone contacts with the patient if (in discretion of the investigator) no 
clinically  relevant changes in vital signs are observed at Visit 3a. Study  procedures have to be 
completed according to the Flow Chart.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 50of 77
Proprietary confidential information © [ADDRESS_424087]-03(12.0)/Saved on:30Jan2015The attendance of the study  partner is not required for Visits 3a -c.The IMP may be taken at 
home at visits 3 a- c.
Visits 4 , 5and EOT
These visits are part of the treatment period. Procedures are to be performed according to the 
flowchart. The recommendations for the performance of the neurops ychological assessments 
should be noted and followed.
Unscheduled visits will be possible at the discretion of the investigator at any time in order to 
check the safet y of the patient.
6.2.3 Follow Up Period and Trial Completion
All randomised patients should be followed up until the end of study at week 16. 
End of Treatment (EOT) Visit:
If the regular end of the treatment period at week 12 is reached or if the patient withdraws 
consent for further participation in the trial the EOT Visit will be completed. The overall 
duration of the treatment period (randomisation to EOT) should n ot be less than [ADDRESS_424088] phone contacts should occur at 
the scheduled visits time points. For patients not attending remaining trial visits or not being 
available for phone contacts replacing the remaining clinic visits a ny attempt will be made to 
get information on vital status at Week 12 (refer to Flow Chart ). Patients will be asked to 
agree to be contact[INVESTIGATOR_530] b y the site personnel, which could be b y telephone calls (in person visit 
would be preferred), to allow collection of this information. If death occurs, the investigator 
will review the circumstances, including the relevant medical records to ascertain the most 
likely  primary  and secondary  causes of death. Collection of vital status will be performed in 
accordance with national ethical and regulatory guidelines. The need for vital status 
inform ation will be explained to patients prior to their participation in the trial.
It is vital to explain to these patients the importance to continue trial participation (please see 
Section 3.3.4 for further details).
All unused st udy medication will be collected and study  drug diary  will be checked. 
Procedures are to be performed according to the Flow C hart.
Follow -up (FU) 1:
This follow -up visit will preferentiall y be performed as a phone contact [CONTACT_342353] (see Flow Chart for procedures 
to be performed ). 
Follow -up ( FU2) 2:
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 51of 77
Proprietary confidential information © [ADDRESS_424089]-03(12.0)/Saved on:30Jan2015This visit is a clinic visit and need to performed 28±3 day  after EOT (see Flow Chart for 
procedures to be performed ).
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 52of 77
Proprietary confidential information © [ADDRESS_424090]-03(12.0)/Saved on:30Jan20157. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
STATISTICAL DESIGN – MODEL 7.1
See Section 3.1 for details on the design of the study .
See Section 2.2 for details on the objective of the study .
A multiple comparison procedure with modelling (MCPMod) approach is considered for
proof -of-concept.   
Further details are included in Section [IP_ADDRESS].
The treatment comparisons for the primary  continuous endpoint will be conducted using a 
restricted maximum likelihood estimation based on mixed model repeated measures analysis. 
Further details are included in 
Section [IP_ADDRESS].
NULL AND ALTERNATIVE HYPOTHESES 7.[ADDRESS_424091] observed measurement prior to administration 
of an y randomised stud y medication.
The null hy pothesis is that t here is a flat dose response pattern across placebo and any dose of 
BI 425809 within the tested dose range (0
-25mg) on mean change in ADAS- Cog 11total score 
from baseline to treatment week 12. 
The alternative hy pothesis is that there is a non
-flat dose re sponse pattern indicating a benefit 
of BI [ADDRESS_424092] protecting the overall probability  of type I error (one-sided alpha of 
0.05) . The pre -specified models and their parameters used for this test are ou
tlined in Section
7.3.1 and Section 7.7.
PLANNED ANALYSES 7.3
Analy sis set
The statistical anal yses will be based on the following patient populations:
Treated Set 
The treated set (TS) is defined as all patients treated with at least one dose of study  
medication. Patients in the treated set will be anal yzed based on the actual treatment received 
at the randomization. The TS will be used for safety  analy ses.
Full Ana lysis Set
The full anal ysis set (F AS) will consist of all randomised patients who were treated with at 
least one dose of study drug and had a baseline and at least one post -baseline on treatment 
efficacy  assessment. 
Patients in the FAS will be analy zed bas ed on the intent -to-treat 
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 53of 77
Proprietary confidential information © [ADDRESS_424093]-03(12.0)/Saved on:30Jan2015principle (i.e., patients in the FAS will be anal yzed based on the planned treatment assigned 
at randomization). The FAS will be used for efficacy  analy ses.
Data from subjects who are screened but not randomised will be listed but not inclu ded in any  
summary  statistics or inferential statistics. Specifications of important protocol violations will 
be provided in the TSAP.
7.3.1 Primary endpoint analyses
[IP_ADDRESS] Primary  anal ysis of the primary  endpoint
The anal yses for PoC and dose -finding will be done using multiple comparison procedures 
and modelling ( MCPmod ) techniques [ R10-1424] for mixed model repeated measures 
(MMRM) [ R15-4293 ], whereb y several possible dose response models (patterns) will be 
evaluated (while keepi[INVESTIGATOR_342336] I error of 5%, 1-sided) to identify  the best -
fitting model or subset of models.  The MMRM model as described in Section [IP_ADDRESS] will be 
fitted for MCPmod .
For the PoC testing and for the sample size calculation, the basic shape of each of the models 
to be tested must be pre -defined.  Six different models will be tested in the anal ysis:  
betamod, emax, sigEmax, linear, linear logistic and logistic . Except in the model ‘betamod’, 
the maximum effect is assumed to be achieved at the maximum dose being tested.  For the 
sample size calculation, the maximum standardized effect size is assumed to be 0.35. Further 
details are given in Section 7.7 .
The active BI 425809 doses are 2 mg, 5 mg, 10 mg, and 25 mg daily .  The following model 
assumptions and resulting graphs ( Figure 7.3 .1.1: 1 ) have been selected to cover both 
plausible and a diverse range of dose response patterns:  
Betamod:          75% of the maximum effect is achieved at 2 mg
                         87.5% of the maximum effect is achieved at 5 mg
                        25% of the maximum effect is achieved at [ADDRESS_424094] achieved at 10 mg
    Scalar parameter = 26
Emax1:              20% of the maximum effect is achieved at 2 mg
sigEmax:            25% of the maximum effect is achieved at 5 mg
                            75% of the maximum effect is achieved at 10 mg
Linear:                 no assumptions needed
Linear logistic no assumptions needed
Logistic:     10% of the maximum effect is achieved at 5 mg 
                           50% of the maximum effect is achieved at [ADDRESS_424095] one model is significant, rejecting the null hy pothesis of a flat 
dose-response relation over 12 weeks for the primary  endpoint (mean change from baseline 
in ADAS -Cog 11total score) jointly
 for each of the candidate dose -response models with a 
contrast test controlled for the famil y-wise error rate (α = 0.05 1 -sided).
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 54of 77
Proprietary confidential information © [ADDRESS_424096]-03(12.0)/Saved on:30Jan2015If PoC is established, the best-fitting model from the above set of sixmodels can be refitted 
to the data without an y parameter assumptions t o generate new estimates of the model 
parameters from the data. The target dose will be obtained via model averaging across the 
significant models based on Akaike Information Criterion (AIC) (the smaller the AIC value 
the better the model fit) . The target dose(s) can then be determined from that model by  
[CONTACT_342354] y 
information. The target dose to be chosen should show a delta of at least 2 points in the mean 
change from baseline ADAS -Cog 11total score at week 12 compared to placebo. This will be 
measured on the modelled efficacy  and onl y doses within the dose range investigated (0mg -
25mg) will be considered although the actual modelling will be performed on a broader range 
of doses includin g extrapolation.
Figure 7.3 .1.1: 1:  Shape of the models within the candidate set
[IP_ADDRESS] Secondary  anal yses of the primary  endpoint
If considered necessary  and for the purpose of further model refinement MCPmod might be 
repeated on the primary  endpoint but with an extended set o f shapes including the original 
candidates. Additionall y to that covariates may  be taken into account in a sensitivity  anal ysis. 
The primary  endpoint will also be anal ysed using a restricted maximum likelihood esti mation 
based on MMRM for the change from baseline in ADAS- Cog 11total score after 12 weeks of 

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 55of 77
Proprietary confidential information © [ADDRESS_424097]-03(12.0)/Saved on:30Jan2015treatment. The model will include fixed, categorical covariates of treatment, visit, baseline 
MMSE ( >20, < 20) and treatment by  [CONTACT_23259], as well as the continuous f ixed 
covariates of baseline and baseline -by-visit interaction. Patient will be considered as random 
effect. The unstructured covariance structure will be used to model the within patient 
measurements . 
The first model to converge will be used as the primary anal ysis. The Kenward- Roger 
approximation will be used to estimate denominator degrees of freedom. Significance tests 
will be based on least -squares means using a two -sided α = 0.05 (two -sided 95% confidence 
intervals). ). Analy ses will be implemented using SAS (version 9.4) PROC MI XED. 
Procedures to follow if the anal ysis fails to converge will be described in the TSAP.
The primary  treatment comparisons will be between the placebo and the different d oses of BI 
[ADDRESS_424098] to the mean change from baseline in the ADAS -Cog 11total score after 
12 weeks of treatment. Adjusted mean change from baseline as well as treatment contrasts 
will be presented together with the 95% confidence intervals. The p rimary  treatment 
comparisons will be the contrast between treatments at the endpoint visit. 
Comparisons between treatment groups will be exploratory  in nature and based on the 
numerical comparison of the respective treatment means .
7.3.2 Secondary endpoint analyses
If considered necessary  a MCPmod approach will also be applied to the s econdary  endpoints.
Comparisons between treatment groups will be exploratory  in nature and based on the 
numerical comparison of the respective treatment means .
More details on the analyses of the secondary  endpoints will be included in the TSAP.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 56of 77
Proprietary confidential information © [ADDRESS_424099]-03(12.0)/Saved on:30Jan20157.3.4 Safety analyses
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities
(MedDRA) coding dictionary . Standard BI summary  tables and listings will be produced. All 
adverse events with an onset between start of treatment and end of the residual effect period 
(REP), a period of [ADDRESS_424100] period will be considered ‘treatment- emergent’. The residual effect 
period is defined as 
[ADDRESS_424101] 
drug intake and deteriorate under treatment will also be considered as ‘treatment -emergent’.
Frequency , severit y, and causal relationship o f adverse events will be tabulated b y system 
organ class and preferred term after coding according to the current version of the Medical 
Dictionary  for Drug Regulatory  Activities (MedDRA). Frequency  tables for all adverse 
events, protocol -specified AESI , serious adverse event (SAE), adverse event leading to death, 
adverse event leading to discontinuation, investigator assessed drug -related adverse event and 
serious adverse event will be generated for treatment- emergent adverse events. I n addition, 
summary  statistics and descriptive analy ses will be conducted for other safety  parameters 
including suicidality  as assessed by  C
-SSRS.
Laboratory  data will be analy sedboth quantitatively  as well as qualitatively. The latter will 
be done via comparison of laborato ry data to their reference ranges. Values outside the 
reference range as well as values defined as clinically  relevant will be highlighted in the 
listings. Treatment groups will be compared descriptively  with regard to distribution 
parameters as well as wi th regard to frequency  and percentage of patients with abnormal 
values or clinicall y relevant abnormal values.
Vital signs, ph ysical examinations, or other safet y-relevant data observed at screening, 
baseline, during the course of the trial and at the end -of-trial evaluation will be assessed with 
regard to possible changes compared to findings befo re start of treatment.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 57of 77
Proprietary confidential information © [ADDRESS_424102]-03(12.0)/Saved on:30Jan2015INTERIM ANALYSES 7.[ADDRESS_424103] model will 
handle missing data based on a likelihood method under the "missing at random” assumpt ion.  
Additional details on the imputation of missing data will be specified in the Trial Statistical 
Analy sis Plan (TSAP) prior to unblinding.
RANDOMISATION 7.6
Eligible patients will be randomly  assigned to one of the 5 treatment groups, with an 
allocation of 1:1:1:1:1 respectively  for BI 425809 2 mg once dail y: BI 425809 5 mg once 
daily : BI 425809 10 mg once dail y: BI 425809 25 mg once daily: placebo once dail y. 
The randomisation will be stratified b y baseline MMSE ( >20, < 20). The randomisation will 
be done in blocks to achieve balanced a llocation.
The randomisation of patients to the treatment groups will be performed via an interactive 
response technology  (IRT). BI will arrange for the randomization and the packaging and 
labelling of trialmedication. The randomization list will be generated using a validated 
system, which involves a pseudo-random number generator so that the resulting treatment 
will be both reproducible and non -predictable. The block size will be documented in the 
CTR. Access to the codes wil l be contr olled and documented.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 58of 77
Proprietary confidential information © [ADDRESS_424104]-03(12.0)/Saved on:30Jan2015DETERMINATION OF SAM PLE SIZE 7.[ADDRESS_424105] size of BI 425809 vs. 
placebo of 0.35 for the primary  endpoint, as well as on the pre -specified model parameters 
listed in Section [IP_ADDRESS]. The assumed 
standardized effect size of 0.35 is based on the 
expectation that BI 425809 has somewhat better efficacy  than AChEIs, for which results are 
summarized in Table 7.7:1 .
Table 7.7: [ADDRESS_424106] sizes for Acet yl Cholinesterase Inhibitors (AChEI)
K Rockwood (2004) [ R15-
5201]
Donepezil 
Galantamine 
Rivastigmine AChEI  Effect size (ES): Median (range)
Low Dose ES =0.15 (0.03- 0.22) 
Medium Dose ES = 0.23 (0.12 -0.29)
High Dose ES =0.28 (0.01
-0.31)
For the PoC anal ysis of the four BI 425809 dose groups vs. placebo using the MCPmod
approach with the parameters as listed in Section 7.3.1 , a sample size of 95 evaluable patients 
per group is needed to establish PoC with 80% average power (one -sided 5% alpha level) .  
An additional 10% of Japanese patients will be added, bringing the total to 105 evaluable 
patients.  The primary  analy sis will be conducted on all p atients, while an internal decision 
making anal ysis will be conducted excluding the Japanese patients.
Assuming that 1 0% of the randomi
sed patients withdraw earl y without providing useful 
information, then 117 randomised patients per group are required. W ith 5 treatment groups, a 
total of 585 patients are required. Table 7.7 : 2below gives the sample size calculations under 
different standardized effect sizes using 1- sided t ype I error rate of 0.05 and 80% power. The 
calculation s for the PoC step have been performed using Dose Finding in the R- package 
[R15-
2001] released on 28 SEP 2014 (depends on R version ≥ 2.15.0) .The R codes for the 
sample size calculations as well as the anal yses using the MCPmod approach will be 
provided in the TSAP.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 59of 77
Proprietary confidential information © [ADDRESS_424107]-03(12.0)/Saved on:30Jan2015Table 7.7: [ADDRESS_424108] sizes for 
the ADAS -Cog 11total score change from baseline with 80% power 
and one -sided alpha of 0.[ADDRESS_424109] size 0.3 0.325 0.35 0.375 0.4
Power = 80%
   N for each active treatment arm 126 107 95 81 71
   N including 10% Japanese patients1139 119 105 90 78
   Total 695 595 525 450 390
   Adjusting for 10% dropout
      N for each treatment arm2154 132 117 100 87
      Total 772 660 585 500 433
1Power = 85%
2Power = 88%
The sample size calculations in Table 7.7: [ADDRESS_424110] 
is used for these exploratory  treatment comparisons without adjustment for multiplicity .
Table 7.7: [ADDRESS_424111] size 0.3 0.325 0.35 0.375 0.4
Power = 85%
N for each active treatment arm 161 137 119 103 91
Power = 80%
N for each active treatment arm 139 118 102 89 78
Power = 75%
N for each treatment arm [ADDRESS_424112] method with equal n’s in nQuery  Advisor 6.01 was used for the 
calculation.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 60of 77
Proprietary confidential information © [ADDRESS_424113]-03(12.0)/Saved on:30Jan20158. INFORMED CONSENT, DA TA PROTECTION, TRIAL
RECORDS
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the I CH Harmonized Tripartite Guideline 
for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs)
, the 
Japanese GCP regulations (Ministry  of Health and Welfare Ordinance No. 28, March 27, 
1997), and relevant regulations .
Standard medical care (prop hylactic, diagnostic and therapeutic procedures) remains in the 
responsibility  of the treating phy sician of the patient.
The Investigator will inform the Sponsor immediately  of any  urgent safety measures taken to 
protect the trialsubjects against any  immediate hazard, and also of an y serious breaches of 
the protocol or of ICH GCP and the Japanese GCP regulations (Ministry  of Health and 
Welfare Ordinance No. 28, March 27, 1997) .
The Boehringer Ingelheim transparency and publication polic y can be found on the following 
web page: t rials.boehringer -ingelheim.com. The rights of the Investigator and of the sponsor 
with regard to publication of the results of this trial are described in the Investigator contract.
As a rule, no trial results should be published prior to finalization of the Clinical Trial Report.
For Japan only : The rights of the investigator / trial site and of the sponsor with regard to 
publication of the results of this trial are described in the investigator contract / trial sit e’s 
contract. As a general rule, no trial results should be published prior to finalisation of the 
Clinical Trial Report.
The certificate of insurance cover is made available to the Investigator and the pat ients , and is
stored in the I SF (Investigator Site File).
TRIAL APPROVAL, PATIENT IN FORMATION, AND INFOR MED 8.[ADDRESS_424114] (IRB) / Independent Ethics Committee 
(IEC) and competent authority  (CA) according to national and international regulations. The 
same applies for the implementation of changes introduced by [CONTACT_15635].
Prior to patient participation in the trial, written informed consent must be obtained from each 
patient (or the patient’s legally
 accepted representative) according to ICH / GCP and to the 
regulatory  and legal requirements of the participating country . Each signature [CONTACT_15649] y dated b y each signatory  and the informed consent and any  additional patient-
information form retained by  [CONTACT_21651]. A sign ed copy  of the 
informed consent and any  additional patient information must be given to each patient or the 
patient’s legall y accepted representative.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 61of 77
Proprietary confidential information © [ADDRESS_424115]-03(12.0)/Saved on:30Jan2015The Investigator must give a full explanation to trial patients by [CONTACT_342355], which is prepared avoiding the use of technical terms and expressions. The patient is 
given sufficient time to consider participation in the trial. The Investigator obtains written 
consent of the patient’s own free will with the informed consent form after confirming that 
the patient understands the contents. The Investigator must sign (or place a seal on) and date 
the informed consent form. I f a trial collaborator has given a supplementary  explanation, the 
trial collaborator also signs (or places a seal on) and dates the informed consent.
Re-consenting may become necessary  when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.
DATA QUALITY ASSURANC
E 8.2
A quality  assurance audit/inspection of this trial may  be conducted by  [CONTACT_1034] ,Sponsor ’s 
designees ,or by [CONTACT_1744] /IECor by  [CONTACT_10200]. The quality  assurance auditor will 
have access to all medical records, the Investigator ’s trial -
related files and correspondence, 
and the informed consent docume ntation of this clinical trial.
RECORDS 8.3
Case Report Forms (CRF ) / (e)CRF for individual patients will be provided by  [CONTACT_1034] .
See Section [IP_ADDRESS] for rules about emergency  code breaks. For drug accountability , refer to 
Section 4.1.8 .
8.3.1 Source documents
Source documents provide evidence for the existence of the patient and substantiate the 
integrit y of the data collected. Source documents are filed at the Investigator ’s site.
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be explained. The Investigator may need to request previous medical records or transfer 
records, depending on the tria l;current medical records must also be available.
Neurops ychological rating scales d ata entered into the Rater Station will be regarded as 
source data . These will be centrally  reviewed and may  be further anal ysed by [CONTACT_342356] . 
For eCRFs all data must be derived from source documents.
For thepaper CRF, the following data need to be derived from source documents:
Patient identification: gender, date or yearof birth (in accordance with local laws and 
regulations)
Patient participation in the trial (substance, trial number, patient number, date patient 
was inf ormed)
Dates of Patient’s visits, including dispensing of trial medication
Medical history  (including trial indication and concomitant diseases, if applicable)
Medication history
Adverse events and outcome events (onset date (mandatory ), and end date (if 
available))
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 62of 77
Proprietary confidential information © [ADDRESS_424116]-03(12.0)/Saved on:30Jan2015Serious adverse events (onset date (mandatory ), and end date (if available))
Concomitant therap y (start date, changes)
Originals or copi[INVESTIGATOR_342337] (in validated electronic format, if available)
Completion of Patient’s Participation in the trial” (end date; in case of premature 
discontinuation document the reason for it).
Prior to allocation of a patient to a treatment into a clinical trial, there must be 
documented evidence in the source data (e.g. medical records) that the trial pa rticipant 
meets all inclusion criteria and does not meet any exclusion criteria. The absence of 
records (either medical records or testing conducted specific for a protocol) to support 
inclusion/exclusion criteria does not make the patient eligible for the clinical trial.
8.3.[ADDRESS_424117] access to source data and documents
The Investigator / institution will permit trial -related monitoring, audits, IRB / IEC review 
and regulatory  inspection, providing direct access to all related source data / documents. 
CRF/eCRF and all source documents, including progress notes and copi[INVESTIGATOR_21616] b y the Sponsor ’s clinical trial 
monitor, auditor and inspection by [CONTACT_21652] (e.g. FDA). The Clinical Research 
Associate (CRA) / on site monitor and auditor may review all CRF / eCRF , and written 
informed consents. The accuracy  of the data will be verified by  [CONTACT_342357] S ection 8.3.1 .
8.3.3 Storage period of records
Trial site(s):
The trial site(s) must retain the source documents and essential documents for a period 
defined b y the Japanese GCP regulation and trial site’s contract with the sponsor.
Sponsor:
The Sponsor must retain the essential documents according to the Sponsor ’s SOPs.
LISTEDNESS AND EXPEDITED REPORTING OF AD VERSE EVENTS 8.4
8.4.1 Listedness
To fulfil the regulatory  requirements for expedited safet y reporting, the Sponsor evaluates 
whether a particular adverse event is "listed", i.e. is a known side effect of the drug or not. 
Therefore, a unique reference document for the evaluation of listedness needs to be provided.
For the BI 425809 this is the current version of the IB[c02155957-
07].
8.4.2 Expedited reporting of adverse events
BI is responsible to fulfil their legal regulatory  reporting obligation and in accordance to the 
requirements defined in this CTP.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 63of 77
Proprietary confidential information © [ADDRESS_424118]-03(12.0)/Saved on:30Jan2015STA TEMENT OF CONFIDENTI ALITY 8.[ADDRESS_424119] parties is prohi bited with the exceptions noted below. 
Patient confidentiality  will be ensured by  [CONTACT_21654].
Treatment data may  be given to the patient’s personal phy sician or to other appropriate 
medical personnel responsible for the patie nt’s welfare. Data generated as a result of the trial 
need to be available for inspection on request b y the participating ph ysicians, the Sponsor ’s 
representatives, b y the IRB / IEC and the regulatory authorities .
TRIAL MILESTONES 8.[ADDRESS_424120] patient in the whole trial
(“Last Patient Out”).
The “ Last Patient Drug Discontinuation ” (LPDD) date is defined as the date on which the 
last patient at an individual trial site ends trial medication (as scheduled per protocol or 
prematurel y). Individual Investigators will be notified of S[LOCATION_003]Rs occurring with the trial 
medication until [ADDRESS_424121].
The IEC / competent authority  in each participating EU member state will be notified about 
the trial milestones according to the respective laws.
A final report of the clinical trial data will be written only  after all patients have completed 
the trial in all countries (EU or non -
EU) to incorporate and consider all data in the report.
The sponsor will submit to the EU database a summary  of th efinal trial results within one 
year from the end of a clinical trial as a whole, regardless of the country  of the last patient 
(EU or non- EU).
For Japan only : when the trial is completed, the Investigato r should inform the head of the 
trial site of the completion in writing, and the head of the trial site should promptly  inform the 
IRB and sponsor of the completion in writing.
PROTOCOL VIOLATIONS 8.7
For Japan only : The investigator should document any  deviation from the protocol r egardless 
of their reasons. Only when the protocol was not followed in order to avoid an immediate 
hazard to trial subjects or for other medically  compelling reason, the principal investigator 
[INVESTIGATOR_21617], and 
retain a cop y of the records.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 64of 77
Proprietary confidential information © [ADDRESS_424122]-03(12.0)/Saved on:30Jan2015COMPENSATION AVAILAB LE TO THE PATIENT IN THE EVENT OF 8.8
TRIAL RELATED INJURY
For Japan only : In the event of health injury  associated with this trial, the Sponsor is 
responsible f or compensation based on the con tract signed by  [CONTACT_21655].
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-
05 Trial Protocol Page 65of 77
Proprietary confidential information © [ADDRESS_424123]-03(12.0)/Saved on:30Jan20159. REFERENCES
PUBLISHED REFERENCES 9.1
R03-0748 Berg L. Clinical dementia rating (CDR). Psychopharmacol Bull 1988. 
24(4):637-639.
R10-
1424 Pi[INVESTIGATOR_17872] J, Bornkamp B, Bretz F. Design and analysis of dose -finding 
studies combining multiple comparisons and modeling procedures. J 
Biopharm Stat 2006. 1 6(5):639 -656.
R10-5092 Cooke SF, Bliss TVP. Plasticity  in the human central nervous s ystem. Brain 
2006. 129:1659-1673.
R10-5095 Ferri CP, Prince M, Brayne C, Brodaty  H, Fratiglioni L , Ganguli M, et al. 
Global prevalence of dementia: a Delphi consensus study . Lancet 2005. 
366:2112-2117.
R10-5102 Reymann KG, Frey  JU. The late maintenance of hippocampal LTP: 
requirements, phases, 's ynaptic tagging', 'late -associativity ' and 
implications. Neuropharmacology 2007. 52:24- 40.
R10-5105 Strauss E von, Viitanen M, Ronchi D de, Winblad B, Fratiglioni L . Aging 
and the occurrence of dementia: findings from a population -based cohort 
with a large sample of nonagenarians. Arch Neurol 1999. 56:587-592.
R10-[ADDRESS_424124] 2003. 
17(2):63-67.
R10-5109 Bliss TVP, Collingridge GL . A sy naptic model of memory : long -term 
potentiation in the hippocampus. Nature 1993. 361:31-39.
R13-4518 Hu NW, Ondrejcak T, Rowan MJ. Glutamate receptors in preclinical 
research on Alzheimer's disease: update on recent advances. Pharmacol 
Biochem Behav 2012. 100:855 -862.
R13-4115 McKhann GM, Knopman DS, Chertkow H, Hy man BT, Jack CR, Kawas 
CH, et al. The diagnosis of dementia due to Alzheimer's disease: 
recommendations from the National Institute on Aging -Alzheimer's 
Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimers Dement 2011. 7:263 -269.
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 66of 77
Proprietary confidential information © [ADDRESS_424125]-03(12.0)/Saved on:30Jan2015R13-[ADDRESS_424126] HY, Ts ai GE. Glutamate signaling in the pathophy siology  
and therap y of schizophrenia. Pharmacol Biochem Behav 2012. 100:665 -
677.
R15-1961 European Medicines Agency  (EMA). Committee for Medicinal Products 
for Human Use (CHMP): qualification opi[INVESTIGATOR_215186]
-Mod as an efficient 
statistical methodology  for model -based design and anal ysis of phase II 
dose finding studies under model uncertainty  (23 January  2014, 
EMA/CHMP/SAWP/757052/2013). 
http://www.ema.europa.eu/docs/en_GB/document_library /Regulatory _and_
procedural_ g uideline/2014/02/WC500161027.pdf (access date: 28 April 
2015) ; L ondon: European Medicines Agency  (EMA) 2014.
R15-2001 Bornkamp B, Pi[INVESTIGATOR_17872] J, Bretz F. Package 'DoseFinding' (February  19, 
2015). http://cran.r -
project.org/web/packages/DoseFinding/DoseFin ding.pdf (access date: 28 
April 2015) ; Comprehensive R Archive Network 2015
R15-4293 Pi[INVESTIGATOR_17872] J, Bornkamp B, Glimm E, Bretz F. Model -based dose finding 
under model uncertaint y using general parametric models. Stat Med 2014. 
33(10):1646-1661.
R15-[ADDRESS_424127] on cognition of cholinesterase 
inhibition in Alzheimer's disease. J Neurol Neurosurg Ps ychiatry  2004. 
75(5):677-685.
R17-3992 Lezak MD, Howieson DB, Loring DW, Hannay  HJ, Fischer JS, editors 
Neurops ychological assess ment. 4th ed. [LOCATION_001]: Oxford University  
Press (2004)
R96-2608 Rosen WG, Mohs RC, Davis KL . A new rating scal e for Alzheimer’s 
disease. Am J Psy chiatry 1984; 141(11): 1356 -1364.
R97-3207 Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M , et al. 
An inventory  to assess activities of daily  living for clinical trials in 
alzheimer's disease. Alzheimer Dis Assoc Disord 1997. 11(2):S33 -S39.

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 67of 77
Proprietary confidential information © [ADDRESS_424128]-03(12.0)/Saved on:30Jan2015UNPUBLISHED REFERENC ES 9.2
c02155957-07 BI 425809 Investigator‘s Broc hure. 04 Dec 2017
c02820512-01 . Safety , toleratility , and 
pharmacokinetics of single rising oral doses of BI 425809 in healthy  male 
subjects (partiall y randomised, single -blind, placebo -controlled) and 
investigation of relative bioavailability  and food effect of BI [ZIP_CODE] 9 (open -
label, randomised, three -way cross -
over). 1346.1. [ADDRESS_424129] of different multiple or aldoses of BI 425809 in 
healthy  male volunteers. 1346.3. 01 Feb2016.
001-MCS -36-472 Boehringer Ingelheim SOP: „Standart Operation Procedure“, current
version, IDEA for CON

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 68of 77
Proprietary confidential information © [ADDRESS_424130]-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 69of 77
Proprietary confidential information © [ADDRESS_424131]-03(12.0)/Saved on:30Jan2015

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 70of 77
Proprietary confidential information © [ADDRESS_424132]-03(12.0)/Saved on:30Jan201511. DESCRIPTION OF GLOBA L AMENDMENT(S)
Number of global amendment [ADDRESS_424133](s) BI 425809
Title of protocol A multi -centre, double -blind, parallel -group, 
randomised controlled study  to investigate efficacy , 
safet y and tolerability of orally administered 
BI409306 during a 12-week treatment period 
compared to placebo in patients with cognitive 
impairment due to Alzheimer’s Disease.
To be implemented only after 
approval of the IRB /IEC /
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approval
Can be implemented without 
IRB /IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed Flowchart, [IP_ADDRESS]
Description of change The eC -SSRS (electronic version) was replaced by 
[CONTACT_941] C -SSRS (paper version) .
Rationale for change The eC -SSRS is an always self -administered 
questionnaire and not available in a rater -
completed version. In the mild -to-moderate 
dementia population studied in this protocol the 
rater-completed C -SSRS is the appropriate tool to 
monitor suicidality .
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 71of 77
Proprietary confidential information © [ADDRESS_424134]-03(12.0)/Saved on:30Jan2015Number of global amendment [ADDRESS_424135](s) BI 425809
Title of protocol A multi -centre, double -blind, parallel -group, 
randomised controlled study  to investigate efficacy , 
safet y and tolerability of orally administered 
BI409306 during a 12-week treatment period 
compared to placebo in patients with cognitive 
impairment due to Alzheimer’s Disease.
To be implemented only after 
approval of the IRB / IEC / 
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approval
Can be implemented without 
IRB / IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed 1.2
Description of change A typo was corrected and information on C YP2b6 
induction was added.
Rationale for change New information was added.
Section to be changed 2.1
Description of change
Rationale for change New information was added.
Section to be changed 3.3.3, [IP_ADDRESS], and [IP_ADDRESS]
Description of change A new exclusion and restrictions on herbal 
medications were added.
Rationale for change Herbal medications that may  potentiall y interfere 
with efficacy  assessments were excluded
Section to be changed 5.4.[ADDRESS_424136] s were removed 

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 72of 77
Proprietary confidential information © [ADDRESS_424137]-03(12.0)/Saved on:30Jan2015from the planned pharmacogenomic analy sis.
Rationale for change A typo was corrected
Number of global amendment [ADDRESS_424138](s) BI 425809
Title of protocol A multi -centre, double -blind, parallel -group, 
randomised controlled study  to investigate efficacy , 
safet y and tolerability of orally administered 
BI409306 during a 12- week treatment p eriod 
compared to placebo in patients with cognitive 
impairment due to Alzheimer’s Disease.
To be implemented only after 
approval of the IRB / IEC / 
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
chang e with request for 
approval
Can be implemented without 
IRB / IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Section to be changed Title page
Description of change Update in Trial Clinical Monitor
Rationale for change Updated information.
Section to be changed Synopsis
Description of change Deletion of CDR from Main criteria 
inclusion 
Primary  Endpoint ADAS -cog 13
(Alzheimer’s Disease Assessment Scale-
cognitive subscale) was changed to ADAS -
cog 11(Alzheimer’s Disease Assessment 
Scale -cognitive subscale)
CDR SB (Clinical Dementia Rating Sum of 
Boxe s) was deleted from Secondary  
Endpoints
CIBIS and CIBIC+ were added among 
Secondary  Endpoints
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 73of 77
Proprietary confidential information © [ADDRESS_424139]-03(12.0)/Saved on:30Jan2015Further editorial changes
Rationale for change New concept to detect efficacy  signal in executive 
function and memory  of the heterogenous AD 
patient popu lation which will be included in this 
trial.
Section to be changed Flow Chart
Description of change Visit 0 was added to allow comfortable 
time window forimaging, review of In/Ex 
Criteria and concomitant medications 
Changes to the structure of 
Neurops ychological Rating Scales ( ADAS -
cog 13(Alzheimer’s Disease Assessment 
Scale -cognitive subscale) changed to 
ADAS -cog 11, CDR SB ( Clinical Dementia 
Rating Sum of Boxes) was deleted,  CIBIS, 
CIBIC+   
were added
Further editorial changes
Rationale for change New concept to detect efficacy  signal in 
executive function and memory  of the 
heterogenous AD patient population which 
will be included in this trial.
Increase clarit y on performance of trial 
related procedures
Section to be changed 1.2
Description of change Sentences Updated “Based on in vitro data, at the 
highest proposed Phase 2 dose of 25 mg, BI 
425809 may  cause clinically  relevant induction of 
CYP2B6. Based on Phase I clinical studies BI 
425809 is a mild CYP3A4 inducer at 25mg” 
Rationale for change Section updated to be in line with current version 
of the IB dated [ADDRESS_424140] shall not be used as an endpoint therefore this 
complicated and long scale was deleted from 
Inclusion Criteria
Section to be changed 3.3.3
Description of change Change in haemoglobin cut -off value, less 

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 74of 77
Proprietary confidential information © [ADDRESS_424141]-03(12.0)/Saved on:30Jan2015strict requirement
Editorial changes
Rationale for change Reflect negligible Hb lowering effect of 
drug on Hb levels therefore allow lower HB 
levels for inclusion
Changes to ease reading and understanding
Section to be changed 3.3.4
Description of change Editorial changes
Rationale for change Increase clarit y of the text
Section to be changed 4.2.2
Description of change Added sentence 
Previous text information on concomitant 
treatments converted into table and 
elaborated further  
Rationale for change Increase clarit y on concomitant treatments, 
emphasize necessit y of stable background 
treatments throughout the trial participation as a ny 
changes may  have direct or indirect impact on 
cognition and the diagnosis under scrutiny    
Section to be changed 5.[ADDRESS_424142] efficacy  signal in executive 
function and memory  of the heterogenous AD 
patient population which will be included in this 
trial.
Section to be changed 5.3.3
Description of change Possibility  to introduce Vitamin B12 and folate 
treatments if values are found abnormal (below 
lower limit normal) at Visit 1.
Rationale for change To allow such patient to participate in the trial, to 
reduce SF rate
Section to be changed 5.3.4
Description of change Text on central and independent anal ysis of ECGs 
added 
Rationale for change To increase objective assessment of ECGs in the 
trial
Section to be changed 5.4.
Description of change Editorial changes   
Rationale for change Simplification of the section  
Section to be changed 6.1

Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 75of 77
Proprietary confidential information © [ADDRESS_424143]-03(12.0)/Saved on:30Jan2015Description of change Editorial and operational changes, more 
explanation on trial conduct and visit planning
Rationale for change Increase understanding and allow more flexibility  
for patient and the site staff in the trial
Section to be changed 6.2.[ADDRESS_424144](s) BI 425809
Title of protocol A multi -centre, double -blind, parallel -group, 
randomised controlled study  to investigate efficacy , 
safet y and tolerability of orally administered 
BI409306 during a 12-week treatment period 
compared to placebo in patients with cognitive 
impairment due to Alzheimer’s Disease.
To be implemented only after 
approval of the IRB / IEC / 
Competent Authorities
To be implemented immediately 
in order to eliminate hazard –
IRB / IEC / Competent 
Authority to be notified of 
change with request for 
approval
Can be implemented without 
IRB / IEC / Competent 
Authority approval as changes 
involve logistical or 
administrative aspects only
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 76of 77
Proprietary confidential information © [ADDRESS_424145]-03(12.0)/Saved on:30Jan2015Section to be changed Flow Chart
Description of change Correct ion of typo in visit window of 
screening period and IRT registration call in 
thus aligning this information  with section 
6.1
Added End of Study  IRT call abnd last dose 
of trial medication information to the Flow 
Chart (previousl y if different sections of the 
protocol )
Correct ion of typo in IRT patient 
registration call (must be at V1 as onl y at 
V1 we may  enter the MMSE score to the 
IRT)
Putting the order of neuropsy chological 
rating scales in line with the rater station 
device the sites are using 
Enable 2 laboratory  re-tests (if needed) in 
screening period to ease operational 
conduct 
Added footnotes 17-20
Correct ion of further minor typos
Rationale for change Editorial changes to increase clarit y of the text and 
align with further sections of the protocol
Section to be changed 1.2
Description of change Correction of typos (C yp →CYP; itroconazole →
itraconazole)
Rationale for change Corrections of t ypos
Section to be changed 3.3.2
Description of change Deletion of duplicated sentence in In. Crit. #4
Rationale for change Editorial change  
Section to be changed 3.3.3
Description of change Rewording of Ex. Crit. #14
Rationale for change Increase clarity due to too many questions being 
raised for this Ex. Crit.  
Section to be changed 4.1.4
Description of change Dose missed by [CONTACT_726] 12 hours should 
be skipped, original text 4 hours (this was a 
typo from previous bid posology)  
Added information on drug administration 
during visits 3a -c and the last trial drug 
administration. 
Rationale for change Typo correction and added information to increase 
clarity  of the text and align with further sections of 
the protocol
Boehringer Ingelheim 12Jul2018
BI Trial No.: 1346.23
c03632269-05 Trial Protocol Page 77of 77
Proprietary confidential information © [ADDRESS_424146]-03(12.0)/Saved on:30Jan2015Section to be changed [IP_ADDRESS]
Description of change Correction of t ypos in table [IP_ADDRESS].1 Central 
Analgesics and Vitamin B12/Folate 
Addition texton Nutritional Support in AD and 
grapefruit juice and St. John’s Wort preparations
Rationale for change Added text to increase clarity  and editorial changes  
Section to be changed 4.2.2
Description of change Rewording of dietary  supplements restrictions to be 
aligned with section [IP_ADDRESS]
Rationale for change Editorial changes to increase clarit y of the protocol
Section to be changed 5.2
Description of change Deletion of inconsistent sentence (coding 
administration time 90 seconds was deleted)   
Rationale for change Inconsistent sentence deleted
Section to be changed 5.3.1
Description of change Added text to enable prope r reporting of abnormal 
findings resulting from phy sical examinations. 
Rationale for change Added text to increase clarity  and top be in line 
with section 5.3.7 of the protocol
Section to be changed 5.3.3; 5.3.4; [IP_ADDRESS] and 5.3.[ADDRESS_424147] of the trial   
Rationale for change Editorial changes
Section to be changed 7.3.5
Description of change Typo corrections   
Rationale for change Editorial changes 
   
 
APPROVAL / SIGNATURE [CONTACT_15650]:  Technical Version Number:  
Document Name:  
  
                                                                                                                  
[CONTACT_1641]:  
 
 
 
                                                                                                                    
Signatures (obtained electronically) 
 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
 
  
  
 
  
  
 
  
  
 
  
  
 
   
  
 
 
  
  
   
 
  
  
   
 
  
  
 c03632269 5.0
clinical-trial-protocol-version-05
A multi-centre, double-blind, parallel-group, randomised controlled study to
investigate efficacy and safety of orally administered BI425809 during a 12-weektreatment period compared to placebo in patients with cognitive impairment due toAlzheimer’s Disease.
Author-Trial Clinical Monitor 13 Jul 2018 11:[ADDRESS_424148]
Author-Trial Clinical
Pharmacokineticist13 Jul 2018 11:[ADDRESS_424149]
Author-Trial Statistician 16 Jul 2018 22:[ADDRESS_424150]
Approval-Therapeutic Area 17 Jul 2018 08:[ADDRESS_424151]
Approval-Team Member Medicine 17 Jul 2018 18:[ADDRESS_424152]

Boehringer Ingelheim Page 2 of 2
Document Number:  Technical Version Number :  
 
 (Continued) Signatures (obtained electronically) 
 
Meaning of Signature  [CONTACT_9719] [CONTACT_9716] 
 
   
  
 
 
  
  
  
 
  
 
    
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 c03632269 5.0